| Year |
Citation |
Score |
| 2024 |
Ci X, Chen S, Zhu R, Zarif M, Jain R, Guo W, Ramotar M, Gong L, Xu W, Singh O, Mansouri S, Zadeh G, Wei GH, Xu W, Bristow R, et al. Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer. Bmc Cancer. 24: 744. PMID 38890593 DOI: 10.1186/s12885-024-12505-1 |
0.36 |
|
| 2024 |
Woodcock DJ, Sahli A, Teslo R, Bhandari V, Gruber AJ, Ziubroniewicz A, Gundem G, Xu Y, Butler A, Anokian E, Pope BJ, Jung CH, Tarabichi M, Dentro SC, Farmery JHR, ... ... Bristow RG, et al. Genomic evolution shapes prostate cancer disease type. Cell Genomics. 100511. PMID 38428419 DOI: 10.1016/j.xgen.2024.100511 |
0.685 |
|
| 2023 |
Houlahan KE, Livingstone J, Fox NS, Kurganovs N, Zhu H, Sietsma Penington J, Jung CH, Yamaguchi TN, Heisler LE, Jovelin R, Costello AJ, Pope BJ, Kishan AU, Corcoran NM, Bristow RG, et al. A polygenic two-hit hypothesis for prostate cancer. Journal of the National Cancer Institute. PMID 36610996 DOI: 10.1093/jnci/djad001 |
0.427 |
|
| 2022 |
Burns D, Anokian E, Saunders EJ, Bristow RG, Fraser M, Reimand J, Schlomm T, Sauter G, Brors B, Korbel J, Weischenfeldt J, Waszak SM, Corcoran NM, Jung CH, Pope BJ, et al. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. European Urology. PMID 35659150 DOI: 10.1016/j.eururo.2022.05.007 |
0.682 |
|
| 2022 |
Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, et al. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology. PMID 35450732 DOI: 10.1016/j.eururo.2022.04.002 |
0.422 |
|
| 2022 |
Lip H, Amini MA, Zetrini A, Cai P, Abbasi AZ, Bristow RG, Rauth AM, Wu XY. Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 35227733 DOI: 10.1016/j.radonc.2022.02.026 |
0.344 |
|
| 2021 |
Livingstone J, Shiah YJ, Yamaguchi TN, Heisler LE, Huang V, Lesurf R, Gebo T, Carlin B, Eng S, Drysdale E, Green J, van der Kwast T, Bristow RG, Fraser M, Boutros PC. The telomere length landscape of prostate cancer. Nature Communications. 12: 6893. PMID 34824250 DOI: 10.1038/s41467-021-27223-6 |
0.65 |
|
| 2021 |
Fraser M, Livingstone J, Wrana JL, Finelli A, He HH, van der Kwast T, Zlotta AR, Bristow RG, Boutros PC. Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nature Communications. 12: 6248. PMID 34716314 DOI: 10.1038/s41467-021-26489-0 |
0.67 |
|
| 2021 |
Ali A, Du Feu A, Oliveira P, Choudhury A, Bristow RG, Baena E. Prostate zones and cancer: lost in transition? Nature Reviews. Urology. PMID 34667303 DOI: 10.1038/s41585-021-00524-7 |
0.438 |
|
| 2021 |
Hawley JR, Zhou S, Arlidge C, Grillo G, Kron KJ, Hugh-White R, van der Kwast TH, Fraser M, Boutros PC, Bristow RG, Lupien M. Reorganization of the 3D genome pinpoints non-coding drivers of primary prostate tumors. Cancer Research. PMID 34642184 DOI: 10.1158/0008-5472.CAN-21-2056 |
0.631 |
|
| 2021 |
Ramotar M, Chua MLK, Truong H, Hosni A, Pintilie M, Davicioni E, Fleshner NE, Dicker AP, Bristow RG, He HH, van der Kwast T, Den RB, Berlin A. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. Urologic Oncology. PMID 34538726 DOI: 10.1016/j.urolonc.2021.08.013 |
0.368 |
|
| 2021 |
Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet (London, England). PMID 34370973 DOI: 10.1016/S0140-6736(21)00950-8 |
0.42 |
|
| 2021 |
Bibby BAS, Thiruthaneeswaran N, Yang L, Pereira RR, More E, McArt DG, O'Reilly P, Bristow RG, Williams KJ, Choudhury A, West CML. Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. Bmc Urology. 21: 96. PMID 34210300 DOI: 10.1186/s12894-021-00856-x |
0.403 |
|
| 2021 |
Glicksman RM, Metser U, Vines D, Valliant J, Liu Z, Chung PW, Bristow RG, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Green D, Bayley A, Helou J, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology. PMID 33685838 DOI: 10.1016/j.eururo.2021.02.031 |
0.401 |
|
| 2021 |
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate cancer. Nature Reviews. Disease Primers. 7: 9. PMID 33542230 DOI: 10.1038/s41572-020-00243-0 |
0.43 |
|
| 2020 |
Rubin MA, Bristow RG, Thienger PD, Dive C, Imielinski M. Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Molecular Cell. 80: 562-577. PMID 33217316 DOI: 10.1016/j.molcel.2020.10.033 |
0.367 |
|
| 2020 |
Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, Boutros P, ... ... Bristow RG, et al. Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. Plos Medicine. 17: e1003281. PMID 32797086 DOI: 10.1371/Journal.Pmed.1003281 |
0.68 |
|
| 2020 |
Armstrong CWD, Coulter JA, Ong CW, Maxwell PJ, Walker S, Butterworth KT, Lyubomska O, Berlingeri S, Gallagher R, O'Sullivan JM, Jain S, Mills IG, Prise KM, Bristow RG, LaBonte MJ, et al. Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. Nar Cancer. 2: zcaa012. PMID 32743555 DOI: 10.1093/narcan/zcaa012 |
0.381 |
|
| 2020 |
Brastianos HC, Murgic J, Salcedo A, Chua MLK, Meng A, Fraser M, Brundage M, Fleshner NE, van der Kwast T, Bristow RG, Boutros PC, Berlin A. Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. European Urology Oncology. PMID 32605887 DOI: 10.1016/J.Euo.2020.06.005 |
0.676 |
|
| 2020 |
Ashton J, Bristow R. Bad neighbours: hypoxia and genomic instability in prostate cancer. The British Journal of Radiology. 20200087. PMID 32551913 DOI: 10.1259/Bjr.20200087 |
0.54 |
|
| 2020 |
Glicksman RM, Metser U, Valliant J, Chung PW, Fleshner NE, Bristow RG, Green D, Finelli A, Hamilton R, Stanescu T, Hussey D, Catton C, Gospodarowicz M, Warde P, Bayley A, et al. [F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. Bmj Open. 10: e035959. PMID 32327479 DOI: 10.1136/Bmjopen-2019-035959 |
0.417 |
|
| 2020 |
Thomas G, Eisenhauer E, Bristow RG, Grau C, Hurkmans C, Ost P, Guckenberger M, Deutsch E, Lacombe D, Weber DC. The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report. European Journal of Cancer (Oxford, England : 1990). 131: 76-88. PMID 32305726 DOI: 10.1016/J.Ejca.2020.02.050 |
0.324 |
|
| 2020 |
Krause M, Alsner J, Linge A, Bütof R, Löck S, Bristow R. Specific requirements for translation of biological research into clinical radiation oncology. Molecular Oncology. PMID 32175659 DOI: 10.1002/1878-0261.12671 |
0.338 |
|
| 2020 |
Rebello RJ, Bristow RG. Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 32147317 DOI: 10.1016/J.Clon.2019.11.002 |
0.483 |
|
| 2020 |
Bhandari V, Li CH, Bristow RG, Boutros PC. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nature Communications. 11: 737. PMID 32024819 DOI: 10.1038/S41467-019-14052-X |
0.376 |
|
| 2020 |
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology. PMID 32001144 DOI: 10.1016/J.Eururo.2020.01.012 |
0.517 |
|
| 2020 |
Zhou S, Hawley JR, Soares F, Grillo G, Teng M, Madani Tonekaboni SA, Hua JT, Kron KJ, Mazrooei P, Ahmed M, Arlidge C, Yun HY, Livingstone J, Huang V, Yamaguchi TN, ... ... Bristow RG, et al. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nature Communications. 11: 441. PMID 31974375 DOI: 10.1038/S41467-020-14318-9 |
0.682 |
|
| 2020 |
Lindsay CR, Nicola P, Jamal-Hanjani M, Wallace A, Wilson G, Burghel G, Schlecht H, Baker K, Baker E, Priest L, Rogan J, Moghadam S, Carter M, Dive C, Bristow RG, et al. Abstract B49: “Triple wild-type” co-mutational profile in early-stage KRAS-mutant lung cancer Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-B49 |
0.372 |
|
| 2019 |
Gillessen S, Bristow RG. The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. The Lancet. Oncology. PMID 31806542 DOI: 10.1016/S1470-2045(19)30780-6 |
0.479 |
|
| 2019 |
Mazrooei P, Kron KJ, Zhu Y, Zhou S, Grillo G, Mehdi T, Ahmed M, Severson TM, Guilhamon P, Armstrong NS, Huang V, Yamaguchi TN, Fraser M, van der Kwast T, Boutros PC, ... ... Bristow RG, et al. Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. Cancer Cell. PMID 31735626 DOI: 10.1016/J.Ccell.2019.10.005 |
0.677 |
|
| 2019 |
Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Yamaguchi TN, ... ... Bristow RG, et al. Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nature Medicine. PMID 31591588 DOI: 10.1038/S41591-019-0579-Z |
0.647 |
|
| 2019 |
Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, Cuizon C, Scarcello S, Jeyapala R, Watson JD, Fraser M, Ray J, Commisso K, Loblaw A, Fleshner NE, ... Bristow RG, et al. Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome. Journal of the National Cancer Institute. PMID 31161221 DOI: 10.1093/Jnci/Djz112 |
0.647 |
|
| 2019 |
Salem A, Little RA, Latif A, Featherstone AK, Babur M, Peset I, Cheung S, Watson Y, Tessyman V, Mistry H, Ashton G, Behan C, Matthews JC, Asselin MC, Bristow RG, et al. Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31053599 DOI: 10.1158/1078-0432.Ccr-18-3932 |
0.35 |
|
| 2019 |
Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, Ignatchenko V, Fritsch K, Donmez N, Heisler LE, Shiah YJ, Yao CQ, Alfaro JA, Volik S, Lapuk A, ... ... Bristow RG, et al. The Proteogenomic Landscape of Curable Prostate Cancer. Cancer Cell. 35: 414-427.e6. PMID 30889379 DOI: 10.1016/J.Ccell.2019.02.005 |
0.723 |
|
| 2019 |
Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP. The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews. Urology. PMID 30808988 DOI: 10.1038/S41585-019-0164-8 |
0.684 |
|
| 2019 |
Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, ... ... Bristow RG, et al. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 176: 831-843.e22. PMID 30735634 DOI: 10.1016/J.Cell.2019.01.025 |
0.63 |
|
| 2019 |
Jiang DM, Jiang H, Chung PWM, Zlotta AR, Fleshner NE, Bristow RG, Berlin A, Kulkarni GS, Alimohamed NS, Lo G, Sridhar SS. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer. 17: 38-45. PMID 30686350 DOI: 10.1016/J.Clgc.2018.09.021 |
0.329 |
|
| 2019 |
Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, ... ... Bristow RG, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications. 10: 278. PMID 30655535 DOI: 10.1038/S41467-018-08133-6 |
0.489 |
|
| 2019 |
Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang X, Espiritu SMG, Heisler LE, Yousif F, Huang V, Yamaguchi TN, ... ... Bristow RG, et al. Molecular landmarks of tumor hypoxia across cancer types. Nature Genetics. PMID 30643250 DOI: 10.1038/S41588-018-0318-2 |
0.61 |
|
| 2019 |
Glicksman R, Sanmamed N, Thoms J, Zlotta AR, Finelli A, van der Kwast T, Sweet J, Jewett M, Klotz LH, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A. A phase I pilot study of pre-operative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes. International Journal of Radiation Oncology, Biology, Physics. PMID 30625410 DOI: 10.1016/J.Ijrobp.2018.12.054 |
0.473 |
|
| 2019 |
Rebello RJ, Oing C, Gillessen S, Bristow RG. and Prognosis in mCRPC Survival: Biology or Coincidence? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30610102 DOI: 10.1158/1078-0432.Ccr-18-3401 |
0.459 |
|
| 2019 |
Rodrigues Pereira R, Miller C, Baena E, Bristow RG. Machine learning approaches to improve prostate cancer outcome. Journal of Clinical Oncology. 37: 82-82. DOI: 10.1200/Jco.2019.37.7_Suppl.82 |
0.414 |
|
| 2019 |
Vinayak B, Liu L, Espirritu S, Lalonde E, Yamaguchi T, Heisler L, Livingstone J, Huang V, Shiah Y, Sabelnykova V, Yousif F, Fraser M, Chua M, Van Der Kwast T, Liu SK, ... ... Bristow RG, et al. The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer. Journal of Clinical Oncology. 37: 81-81. DOI: 10.1200/Jco.2019.37.7_Suppl.81 |
0.723 |
|
| 2019 |
Brastianos H, Murgic J, Salcedo A, Chua MLK, Meng A, Fraser M, Brundage MD, Fleshner NE, van der Kwast T, Bristow RG, Boutros PC, Berlin A. The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer. Journal of Clinical Oncology. 37: 46-46. DOI: 10.1200/Jco.2019.37.7_Suppl.46 |
0.666 |
|
| 2019 |
Nicola PA, Burghel G, Wallace A, Schlecht H, Baker E, Baker K, Priest L, Carter M, Moghadam S, Rogan J, Bristow RG, Newman W, Blackhall F, Lindsay CR. Abstract 1763: Tumor mutational burden, mutational signatures and copy number variation in lung cancer driven by the Ras-Raf-MEK-ERK pathway Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1763 |
0.309 |
|
| 2019 |
Trudel D, Grosset A, Dallaire F, Nguyen T, Kougioumoutzakis A, Azzi F, Aubertin K, Saad F, Latour M, Albadine R, Boutros P, Fraser M, Bristow RG, Kwast Tvd, Benzerdjeb N, et al. Raman microscopy for the identification of an aggressive variant of prostate cancer, intraductal carcinoma of the prostate Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz239.002 |
0.661 |
|
| 2018 |
Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, ... ... Bristow RG, et al. Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell. 34: 996-1011.e8. PMID 30537516 DOI: 10.1016/J.Ccell.2018.10.016 |
0.559 |
|
| 2018 |
Cooper CI, Yao D, Sendorek DH, Yamaguchi TN, P'ng C, Houlahan KE, Caloian C, Fraser M, Ellrott K, Margolin AA, Bristow RG, Stuart JM, Boutros PC. Valection: design optimization for validation and verification studies. Bmc Bioinformatics. 19: 339. PMID 30253747 DOI: 10.1186/S12859-018-2391-Z |
0.512 |
|
| 2018 |
Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, et al. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. Bmc Urology. 18: 78. PMID 30200929 DOI: 10.1186/S12894-018-0392-X |
0.495 |
|
| 2018 |
Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, et al. Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy. International Journal of Radiation Oncology, Biology, Physics. PMID 30170099 DOI: 10.1016/J.Ijrobp.2018.08.030 |
0.706 |
|
| 2018 |
Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, ... ... Bristow RG, et al. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. Ebiomedicine. PMID 29729848 DOI: 10.1016/J.Ebiom.2018.04.019 |
0.518 |
|
| 2018 |
Bristow RG, Alexander B, Baumann M, Bratman SV, Brown JM, Camphausen K, Choyke P, Citrin D, Contessa JN, Dicker A, Kirsch DG, Krause M, Le QT, Milosevic M, Morris ZS, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. The Lancet. Oncology. 19: e240-e251. PMID 29726389 DOI: 10.1016/S1470-2045(18)30096-2 |
0.396 |
|
| 2018 |
Espiritu SMG, Liu LY, Rubanova Y, Bhandari V, Holgersen EM, Szyca LM, Fox NS, Chua MLK, Yamaguchi TN, Heisler LE, Livingstone J, Wintersinger J, Yousif F, Lalonde E, Rouette A, ... ... Bristow RG, et al. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. Cell. PMID 29681457 DOI: 10.1016/J.Cell.2018.03.029 |
0.702 |
|
| 2018 |
Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, ... ... Bristow RG, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics. PMID 29662167 DOI: 10.1038/S41588-018-0086-Z |
0.705 |
|
| 2018 |
Böttcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, Yousif F, Fraser M, Bristow RG, van der Kwast T, Boutros PC, Jenster G, van Leenders GJLH. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. Bmc Cancer. 18: 8. PMID 29295717 DOI: 10.1186/S12885-017-3976-Z |
0.703 |
|
| 2018 |
Chua M, Murgic J, Hosni A, Salcedo A, Kamel-Reid S, Berlin A, Pintile M, Fraser M, Van Der Kwast T, Boutros PC, Bristow RG. A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer. Journal of Clinical Oncology. 36: 68-68. DOI: 10.1200/Jco.2018.36.6_Suppl.68 |
0.687 |
|
| 2018 |
Choudhury A, Yang L, Roberts D, Takhar M, Vinayak B, Bibby B, Cheng W, Haider S, Thiruthaneeswaran N, Hoskin P, McArt D, Jain S, Buffa FM, Erho N, Bristow RG, et al. Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer. Journal of Clinical Oncology. 36: 5-5. DOI: 10.1200/Jco.2018.36.6_Suppl.5 |
0.525 |
|
| 2018 |
Porter LH, Lawrence MG, Pezaro C, Thorne H, Ilic D, Papargiris M, Fraser M, Livingstone J, Murphy DG, Frydenberg M, Bolton D, Moon D, Clouston D, Kwast Tvd, Boutros PC, ... Bristow RG, et al. Abstract B100: High-risk pathologic and genomic features of BRCA2-mutant prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B100 |
0.721 |
|
| 2018 |
Fraser ME, Kwast Tvd, Bristow RG. Abstract NG06: The clinico-genomics of localized, non-indolent prostate cancer: the CPC-GENE experience Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ng06 |
0.737 |
|
| 2018 |
Chua M, Bristow R, Murgic J, Hosni Abdalaty A, Salcedo A, Kamel-Reid S, Fraser M, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, Van der Kwast T, Boutros P, Berlin A. A Biopsy Based Genomic Classifier Predicts Biochemical Failure and Metastasis after Definitive Radiation without Hormone Therapy in a Prospective Cohort of Intermediate-Risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S99. DOI: 10.1016/J.Ijrobp.2018.06.254 |
0.688 |
|
| 2017 |
Fraser M, Boutros PC, Bristow RG. A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer. European Urology. PMID 29275835 DOI: 10.1016/J.Eururo.2017.11.029 |
0.698 |
|
| 2017 |
Berlin A, Ahmad AE, Chua MLK, Moraes FY, Jiang H, Komisarenko M, Trimilshina N, Raziee H, Hosni A, Murgic J, Chung P, Bristow RG, Finelli A. Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-Front Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 29249526 DOI: 10.1016/J.Ijrobp.2017.10.041 |
0.453 |
|
| 2017 |
Borst GR, Kumareswaran R, Yücel H, Telli S, Do T, McKee T, Zafarana G, Jonkers J, Verheij M, O'Connor MJ, Rottenberg S, Bristow RG. Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. Oncotarget. 8: 87638-87646. PMID 29152107 DOI: 10.18632/Oncotarget.20936 |
0.41 |
|
| 2017 |
Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, et al. The Future of Radiobiology. Journal of the National Cancer Institute. PMID 29126306 DOI: 10.1093/Jnci/Djx231 |
0.33 |
|
| 2017 |
Sendorek DH, Lalonde E, Yao CQ, Sabelnykova VY, Bristow RG, Boutros PC. NanoStringNormCNV: Pre-processing of NanoString CNV data. Bioinformatics (Oxford, England). PMID 29112706 DOI: 10.1093/Bioinformatics/Btx707 |
0.325 |
|
| 2017 |
Hopkins JF, Sabelnykova VY, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, Heisler LE, Zhang J, Watson JD, Chua MLK, Fraser M, Favero F, Lawerenz C, Plass C, Sauter G, ... ... Bristow RG, et al. Mitochondrial mutations drive prostate cancer aggression. Nature Communications. 8: 656. PMID 28939825 DOI: 10.1038/S41467-017-00377-Y |
0.65 |
|
| 2017 |
Kron KJ, Murison A, Zhou S, Huang V, Yamaguchi TN, Shiah YJ, Fraser M, van der Kwast T, Boutros PC, Bristow RG, Lupien M. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nature Genetics. PMID 28783165 DOI: 10.1038/Ng.3930 |
0.678 |
|
| 2017 |
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology. PMID 28655541 DOI: 10.1016/J.Eururo.2017.06.002 |
0.526 |
|
| 2017 |
Mahamud O, So J, Chua MLK, Bristow RG. Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. Current Problems in Cancer. PMID 28641873 DOI: 10.1016/J.Currproblcancer.2017.04.002 |
0.346 |
|
| 2017 |
Shiah YJ, Fraser M, Bristow RG, Boutros PC. Comparison of Pre-processing Methods for Infinium HumanMethylation450 BeadChip Array. Bioinformatics (Oxford, England). PMID 28605401 DOI: 10.1093/Bioinformatics/Btx372 |
0.553 |
|
| 2017 |
Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, ... ... Bristow RG, et al. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology. PMID 28511883 DOI: 10.1016/J.Eururo.2017.04.034 |
0.704 |
|
| 2017 |
Raziee H, Moraes FY, Murgic J, Chua MLK, Pintilie M, Chung P, Ménard C, Bayley A, Gospodarowicz M, Warde P, Craig T, Catton C, Bristow RG, Jaffray DA, Berlin A. Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28434799 DOI: 10.1016/J.Radonc.2017.04.003 |
0.465 |
|
| 2017 |
Nasser NJ, Thoms J, Soosaipillai A, Pintilie M, Wang R, Diamandis EP, Bristow RG. Human tissue Kallikreins: Blood levels and response to radiotherapy in intermediate risk prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28427756 DOI: 10.1016/J.Radonc.2017.03.023 |
0.486 |
|
| 2017 |
Chua MLK, van der Kwast TH, Bristow RG. Intraductal Carcinoma of the Prostate: Anonymous to Ominous. European Urology. PMID 28416351 DOI: 10.1016/J.Eururo.2017.04.004 |
0.431 |
|
| 2017 |
Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016692327. PMID 28410011 DOI: 10.1200/Jco.2016.69.2327 |
0.394 |
|
| 2017 |
Berton S, Cusan M, Segatto I, Citron F, D'Andrea S, Benevol S, Avanzo M, Dall'Acqua A, Schiappacassi M, Bristow RG, Belletti B, Baldassarre G. Loss of p27(kip1) increases genomic instability and induces radio-resistance in luminal breast cancer cells. Scientific Reports. 7: 595. PMID 28377607 DOI: 10.1038/S41598-017-00734-3 |
0.392 |
|
| 2017 |
Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Juvet T, Prassas I, Trachtenberg J, Toi A, Fraser M, ... ... Bristow RG, et al. Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute. 109. PMID 28376164 DOI: 10.1093/Jnci/Djw258 |
0.707 |
|
| 2017 |
Hosni A, Rosewall T, Craig T, Kong V, Bayley A, Berlin A, Bristow R, Catton C, Warde P, Chung P. The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiation Oncology (London, England). 12: 50. PMID 28279179 DOI: 10.1186/S13014-017-0787-Y |
0.513 |
|
| 2017 |
Weinberg BA, Gowen K, Lee TK, Ou SI, Bristow R, Krill L, Almira-Suarez MI, Ali SM, Miller VA, Liu SV, Klempner SJ. Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. The Oncologist. PMID 28193735 DOI: 10.1634/theoncologist.2015-0511 |
0.33 |
|
| 2017 |
Murphy DG, Risbridger GP, Bristow RG, Sandhu S. The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. European Urology. PMID 28131466 DOI: 10.1016/J.Eururo.2017.01.025 |
0.496 |
|
| 2017 |
Cui L, Her S, Dunne M, Borst GR, De Souza R, Bristow RG, Jaffray DA, Allen C. Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts. Radiation Research. PMID 28085639 DOI: 10.1667/Rr14578.1 |
0.322 |
|
| 2017 |
Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, ... ... Bristow RG, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. PMID 28068672 DOI: 10.1038/Nature20788 |
0.694 |
|
| 2017 |
Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, ... ... Bristow RG, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nature Communications. 8: 13671. PMID 28067867 DOI: 10.1038/Ncomms13671 |
0.688 |
|
| 2017 |
Fox NS, Lalonde E, Livingstone J, Hopkins J, Shiah Y, Huang V, Yamaguchi T, Sabelnykova V, Heisler L, Fraser M, van der Kwast T, Bristow RG, Boutros PC. Integrated somatic subtypes of localized intermediate-risk prostate cancer. Journal of Clinical Oncology. 35: e560-e560. DOI: 10.1200/Jco.2017.35.6_Suppl.E560 |
0.704 |
|
| 2017 |
Ahmad A, Chua M, Murgic J, Raziee HR, Hosni A, Moraes FYD, Timilshina N, Bristow RG, Berlin A, Finelli A. Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer. Journal of Clinical Oncology. 35: 42-42. DOI: 10.1200/Jco.2017.35.6_Suppl.42 |
0.449 |
|
| 2017 |
Chua M, Holgersen E, Sabelnykova V, Salcedo A, Meng A, Fraser M, Van Der Kwast T, Boutros PC, Bristow RG. Genomic architecture of radioresistant prostate cancer. Journal of Clinical Oncology. 35: 26-26. DOI: 10.1200/Jco.2017.35.6_Suppl.26 |
0.724 |
|
| 2017 |
Mahamud O, Chua MLK, Lo W, Zafarana G, Bristow RG. Abstract B39: Tumor hypoxia induces DNA repair vulnerabilities through contextual “loss-of- heterozygosity” Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B39 |
0.354 |
|
| 2017 |
Chua MLK, Holgersen E, Sabelnykova V, Salcedo A, Meng A, Fraser M, Kwast Tvd, Boutros PC, Bristow RG. Abstract 5860: Genomic architecture of prostate cancer at recurrence following radiotherapy Cancer Research. 77: 5860-5860. DOI: 10.1158/1538-7445.Am2017-5860 |
0.708 |
|
| 2017 |
Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, ... ... Bristow RG, et al. PD65-01 GERMLINE MUTATIONS IN THE KALLIKREIN 6 REGION AND PREDISPOSITION FOR AGGRESSIVE PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2951 |
0.614 |
|
| 2017 |
Sundaramurthy A, Kong V, Helou J, Rosewall T, Craig T, Bristow R, Berlin A, Chung P. Deformable Dose Accumulation to Assess Rectal Sparing Associated With Adaptive Radiation Therapy for Bladder Cancer International Journal of Radiation Oncology*Biology*Physics. 99: E266-E267. DOI: 10.1016/J.Ijrobp.2017.06.1239 |
0.365 |
|
| 2016 |
Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. Plos One. 11: e0167272. PMID 28033382 DOI: 10.1371/Journal.Pone.0167272 |
0.393 |
|
| 2016 |
Chowdhury S, Yung E, Pintilie M, Muaddi H, Chaib S, Yeung M, Fusciello M, Sykes J, Pitcher B, Hagenkort A, McKee T, Vellanki R, Chen E, Bristow RG, Wouters BG, et al. MATE2 Expression Is Associated with Cancer Cell Response to Metformin. Plos One. 11: e0165214. PMID 27959931 DOI: 10.1371/Journal.Pone.0165214 |
0.331 |
|
| 2016 |
Fotouhi Ghiam A, Taeb S, Huang X, Huang V, Ray J, Scarcello S, Hoey C, Jahangiri S, Fokas E, Loblaw A, Bristow RG, Vesprini D, Boutros P, Liu SK. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. Oncotarget. PMID 27902466 DOI: 10.18632/Oncotarget.13576 |
0.448 |
|
| 2016 |
Lieng H, Pintilie M, Bayley A, Berlin A, Bristow R, Chung P, Gospodarowicz M, Huang R, Ménard C, Warde P, Catton C. Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 27838147 DOI: 10.1016/J.Radonc.2016.10.017 |
0.479 |
|
| 2016 |
Lalonde E, Alkallas R, Chua ML, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, ... ... Bristow RG, et al. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology. PMID 27815082 DOI: 10.1016/J.Eururo.2016.10.013 |
0.704 |
|
| 2016 |
Ghiam AF, Taeb S, Huang X, Jahangiri S, Ray J, Hoey C, Fokas E, Vesprini D, Bristow RG, Boutros PC, Liu SK. The Biological Role and Clinical Significance of Long Noncoding RNA Urothelial Carcinoma Associated 1 (UCA1) in Prostate Cancer (PCa). International Journal of Radiation Oncology, Biology, Physics. 96: S56. PMID 27675961 DOI: 10.1016/J.Ijrobp.2016.06.145 |
0.463 |
|
| 2016 |
Lieng H, Pintilie M, Berlin A, Bayley A, Bristow RG, Chung P, Gospodarowicz MK, Menard C, Warde PR, Catton CN. Long-Term Outcomes of a Phase 2 Trial of Moderate Hypofractionated Image Guided Intensity Modulated Radiation Therapy (IG-IMRT) for Localized Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: S32-S33. PMID 27675903 DOI: 10.1016/J.Ijrobp.2016.06.092 |
0.437 |
|
| 2016 |
Chua ML, Salcedo A, Meng A, Zhang J, Fleshner N, Fraser M, van der Kwast T, Boutros PC, Bristow RG. Genomic Architecture of Prostate Cancer at Recurrence Following Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. 96: S114. PMID 27675559 DOI: 10.1016/J.Ijrobp.2016.06.280 |
0.696 |
|
| 2016 |
So J, Chua ML, Lalonde E, Pra AD, Berlin A, Orain M, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Livingstone J, Pintilie M, ... ... Bristow RG, et al. Prognostic Significance of Tonsil Expression and the Homologous Recombination Pathway in Intermediate-Risk Prostate Cancer Recurrence. International Journal of Radiation Oncology, Biology, Physics. 96: S113. PMID 27675557 DOI: 10.1016/j.ijrobp.2016.06.278 |
0.665 |
|
| 2016 |
Raziee H, Murgic J, Pintilie M, Chung P, Menard C, Bayley A, Gospodarowicz M, Warde PR, Bristow RG, Catton CN, Berlin A. Assessment of Biochemical Outcomes with Increasing Dose Escalation in Localized Prostate Cancer (PCa) Treated with Precision Image Guided Radiation Therapy (IGRT). International Journal of Radiation Oncology, Biology, Physics. 96: E228-E229. PMID 27674117 DOI: 10.1016/J.Ijrobp.2016.06.1199 |
0.474 |
|
| 2016 |
Smith AD, Truong M, Bristow R, Yip P, Milosevic MF, Joshua AM. The Utility of Serum CA9 for Prognostication in Prostate Cancer. Anticancer Research. 36: 4489-4492. PMID 27630286 DOI: 10.21873/Anticanres.10994 |
0.389 |
|
| 2016 |
Guturi KK, Bohgaki M, Bohgaki T, Srikumar T, Ng D, Kumareswaran R, El Ghamrasni S, Jeon J, Patel P, Eldin MS, Bristow R, Cheung P, Stewart GS, Raught B, Hakem A, et al. RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation. Nature Communications. 7: 12638. PMID 27558965 DOI: 10.1038/Ncomms12638 |
0.366 |
|
| 2016 |
Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J, Li Y, Poon C, Bailey SD, Desai K, Fei T, ... ... Bristow RG, et al. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics. PMID 27526323 DOI: 10.1038/Ng.3637 |
0.701 |
|
| 2016 |
Masella AP, Lalansingh CM, Sivasundaram P, Fraser M, Bristow RG, Boutros PC. BAMQL: a query language for extracting reads from BAM files. Bmc Bioinformatics. 17: 305. PMID 27516195 DOI: 10.1186/S12859-016-1162-Y |
0.505 |
|
| 2016 |
Castelo-Branco P, Leão R, Lipman T, Campbell B, Lee D, Price A, Zhang C, Heidari A, Stephens D, Boerno S, Coelho H, Gomes A, Domingos C, Apolonio JD, Schäfer G, ... Bristow RG, et al. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: A retrospective cohort study. Oncotarget. PMID 27437772 DOI: 10.18632/Oncotarget.10639 |
0.529 |
|
| 2016 |
Tan Q, Wang M, Yu M, Zhang J, Bristow RG, Hill RP, Tannock IF. Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors. Neoplasia (New York, N.Y.). 18: 347-55. PMID 27292024 DOI: 10.1016/J.Neo.2016.04.003 |
0.322 |
|
| 2016 |
McPartlin AJ, Glicksman R, Pintilie M, Tsuji D, Mok G, Bayley A, Chung P, Bristow RG, Gospodarowicz MK, Catton CN, Milosevic M, Warde PR. PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer. Cancer. PMID 27219522 DOI: 10.1002/Cncr.30093 |
0.45 |
|
| 2016 |
Jin CS, Overchuk M, Cui L, Wilson BC, Bristow RG, Chen J, Zheng G. Nanoparticle-enabled selective destruction of prostate tumor using MRI-guided focal photothermal therapy. The Prostate. PMID 27198587 DOI: 10.1002/Pros.23203 |
0.398 |
|
| 2016 |
Chua ML, Bristow RG. Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27166396 DOI: 10.1158/1078-0432.Ccr-16-0381 |
0.409 |
|
| 2016 |
Her S, Cui L, Bristow RG, Allen C. Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer. Radiation Research. PMID 27135970 DOI: 10.1667/Rr14315.1 |
0.358 |
|
| 2016 |
Nayan M, Bhindi B, Yu JL, Mamdani M, Fleshner NE, Hermanns T, Chung P, Milosevic M, Bristow R, Warde P, Hamilton RJ, Finelli A, Jewett MA, Zlotta AR, Sridhar SS, et al. The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 10: 25-30. PMID 26977202 DOI: 10.5489/Cuaj.3315 |
0.361 |
|
| 2016 |
Wang CR, Mahmood J, Zhang QR, Vedadi A, Warrington J, Ou N, Bristow RG, Jaffray DA, Lu QB. In Vitro and In Vivo Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer. Molecular Cancer Therapeutics. PMID 26921393 DOI: 10.1158/1535-7163.Mct-15-0862 |
0.42 |
|
| 2016 |
Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG. Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Frontiers in Oncology. 6: 24. PMID 26909338 DOI: 10.3389/Fonc.2016.00024 |
0.497 |
|
| 2016 |
Boutros PC, Fraser M, van der Kwast T, Bristow RG. Clonality of localized and metastatic prostate cancer. Current Opinion in Urology. 26: 219-24. PMID 26885716 DOI: 10.1097/Mou.0000000000000279 |
0.7 |
|
| 2016 |
Chua M, Lalonde E, Mahamud O, Berlin A, Pra AD, Orain M, Picard V, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Livingstone J, ... ... Bristow RG, et al. Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP). Journal of Clinical Oncology. 34: 96-96. DOI: 10.1200/Jco.2016.34.2_Suppl.96 |
0.637 |
|
| 2016 |
So J, Chua M, Lalonde E, Mahamud O, Berlin A, Dal Pra A, Orain M, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Livingstone J, ... ... Bristow RG, et al. Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence. Journal of Clinical Oncology. 34: 49-49. DOI: 10.1200/Jco.2016.34.2_Suppl.49 |
0.7 |
|
| 2016 |
Kulkarni GS, Hermanns T, Li K, Wei Y, Bhindi B, Kuk C, Sridhar SS, van der Kwast T, Chung PWM, Bristow RG, Warde PR, Milosevic MF, Fleshner NE, Jewett MA, Zlotta A. Impact of multidisciplinary bladder cancer care for muscle invasive bladder cancer: A propensity score matched analysis of survival outcomes. Journal of Clinical Oncology. 34: 455-455. DOI: 10.1200/Jco.2016.34.2_Suppl.455 |
0.396 |
|
| 2016 |
Mahamud O, Chua M, Lalonde E, So J, Dal Pra A, Berlin A, Orain M, Picard V, Hovington H, Bergeron A, Fradet Y, Têtu B, Zafarana G, Meng A, Livingstone J, ... ... Bristow RG, et al. Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer. Journal of Clinical Oncology. 34: 117-117. DOI: 10.1200/Jco.2016.34.2_Suppl.117 |
0.627 |
|
| 2016 |
Murgic J, Berlin A, Chua M, Pintilie M, Bristow RG, van der Kwast T. Intraductal carcinoma and cribriform architecture as novel prognostic factors in patients with prostate cancer treated with dose-escalated radiotherapy. Journal of Clinical Oncology. 34: 101-101. DOI: 10.1200/Jco.2016.34.2_Suppl.101 |
0.434 |
|
| 2016 |
Chua M, Murgic J, Pintilie M, Lalonde E, Berlin A, Livingstone J, Dal Pra A, Meng A, Zhang J, Fradet Y, Têtu B, Fleshner NE, Fraser M, Boutros P, van der Kwast T, ... Bristow RG, et al. Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer. Journal of Clinical Oncology. 34: 5051-5051. DOI: 10.1200/Jco.2016.34.15_Suppl.5051 |
0.708 |
|
| 2016 |
Hopkins JF, Sabelnykova VY, Watson J, Heisler LE, Zhang J, Fraser M, Kwast Tvd, Bristow RG, Boutros PC. Abstract 98: The somatic mutational landscape of the mitochondrial genome in prostate cancer: evaluation of clinical impact Cancer Research. 76: 98-98. DOI: 10.1158/1538-7445.Am2016-98 |
0.681 |
|
| 2016 |
Amini MA, Abbasi AZ, Gordijo CR, Cai P, Rauth AM, Bristow RG, Wu XY. Abstract 745: Hybrid bioactive nanoparticles for modulating prostate tumor microenvironment and enhancing radiation therapy Cancer Research. 76: 745-745. DOI: 10.1158/1538-7445.Am2016-745 |
0.385 |
|
| 2016 |
Chua MLK, Murgic J, Pintilie M, Lalonde E, Kweldam C, Lo W, Berlin A, Pra AD, Orain M, Picard V, Hovington H, Begeron A, Fradet Y, Tetu B, Livingstone J, ... ... Bristow R, et al. Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture Cancer Research. 76: 4339-4339. DOI: 10.1158/1538-7445.Am2016-4339 |
0.677 |
|
| 2016 |
Fraser ME, Kwast Tvd, McPherson J, Collins CC, Fradet Y, Tetu B, Bergeron A, Bristow RG, Boutros PC. Abstract 118: A comprehensive profile of the genomic architecture of curable prostate cancer Cancer Research. 76: 118-118. DOI: 10.1158/1538-7445.Am2016-118 |
0.717 |
|
| 2016 |
So J, Chua M, Lalonde E, Mahamud O, Berlin A, Pra AD, Orain M, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Pintilie M, ... ... Bristow RG, et al. 227: Prognostic Significance of Tonsl Expression and the Homologous Recombination Pathway in Intermediate-Risk Prostate Cancer Recurrence Radiotherapy and Oncology. 120: S82-S83. DOI: 10.1016/S0167-8140(16)33626-X |
0.697 |
|
| 2016 |
Ghiam AF, Taeb S, Huang X, Jahangiri S, Ray J, Hoey C, Fokas EF, Vesprini D, Bristow R, Boutros P, Liu S. 25: CARO Fellowship the Biological Role and Clinical Significance of Long Non-Coding RNA Urothelial Carcinoma Associated 1 (UCA1) in Prostate Cancer (PCA) Radiotherapy and Oncology. 120: S10. DOI: 10.1016/S0167-8140(16)33424-7 |
0.451 |
|
| 2016 |
Chung P, Berlin A, Rink A, Carlone M, Abed J, Simeonov A, O'Leary G, Bayley A, Catton C, Bristow R, Lao B, Menard C. Preliminary Results of MR-Guided Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer after Primary Radiotherapy Brachytherapy. 15: S200. DOI: 10.1016/J.Brachy.2016.04.370 |
0.51 |
|
| 2016 |
McPartlin A, Menard C, Craig T, Lee J, Rink A, Bayley A, Berlin A, Bristow R, Catton C, Gospodarowicz M, Warde P, Chung P. Dosimetric and Early Outcome Data Following an Integrated VMAT or HDR Brachytherapy Boost with External Beam Radiotherapy for Localized Prostate Cancer Brachytherapy. 15: S52-S53. DOI: 10.1016/J.Brachy.2016.04.067 |
0.467 |
|
| 2015 |
Rajan A, Berns A, Ringborg U, Celis J, Ponder B, Caldas C, Livingston D, Bristow RG, Hecht TT, Tursz T, van Luenen H, Bono P, Helander T, Seamon K, Smyth JF, et al. Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies. Molecular Oncology. PMID 26797050 DOI: 10.1016/J.Molonc.2015.12.007 |
0.389 |
|
| 2015 |
Hill RP, Bristow RG, Fyles A, Koritzinsky M, Milosevic M, Wouters BG. Hypoxia and Predicting Radiation Response. Seminars in Radiation Oncology. 25: 260-72. PMID 26384274 DOI: 10.1016/J.Semradonc.2015.05.004 |
0.379 |
|
| 2015 |
Gani C, Coackley C, Kumareswaran R, Schütze C, Krause M, Zafarana G, Bristow RG. In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 116: 486-94. PMID 26277432 DOI: 10.1016/J.Radonc.2015.08.003 |
0.477 |
|
| 2015 |
Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, ... ... Bristow RG, et al. Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics. 47: 689. PMID 26018901 DOI: 10.1038/Ng0615-689B |
0.69 |
|
| 2015 |
Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, ... ... Bristow RG, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics. 47: 736-45. PMID 26005866 DOI: 10.1038/Ng.3315 |
0.68 |
|
| 2015 |
Siadat F, Sykes J, Zlotta AR, Aldaoud N, Egawa S, Pushkar D, Kuk C, Bristow RG, Montironi R, van der Kwast T. Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. The Prostate. 75: 1277-84. PMID 25963383 DOI: 10.1002/Pros.23009 |
0.5 |
|
| 2015 |
Berlin A, Cho E, Kong V, Howell KJ, Lao B, Craig T, Bayley A, Chung P, Gospodarowicz M, Warde P, Catton C, Bristow RG, Ménard C. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Practical Radiation Oncology. PMID 25899220 DOI: 10.1016/J.Prro.2015.02.015 |
0.431 |
|
| 2015 |
Dodbiba L, Teichman J, Fleet A, Thai H, Starmans MH, Navab R, Chen Z, Girgis H, Eng L, Espin-Garcia O, Shen X, Bandarchi B, Schwock J, Tsao MS, El-Zimaity H, ... ... Bristow RG, et al. Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. Plos One. 10: e0121872. PMID 25826681 DOI: 10.1371/Journal.Pone.0121872 |
0.352 |
|
| 2015 |
Locke JA, Dal Pra A, Supiot S, Warde P, Bristow RG. Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nature Reviews. Urology. 12: 193-204. PMID 25800395 DOI: 10.1038/Nrurol.2015.50 |
0.511 |
|
| 2015 |
Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, ... ... Bristow RG, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics. 47: 367-72. PMID 25730763 DOI: 10.1038/Ng.3221 |
0.697 |
|
| 2015 |
Rybak AP, Bristow RG, Kapoor A. Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget. 6: 1900-19. PMID 25595909 DOI: 10.18632/Oncotarget.2953 |
0.504 |
|
| 2015 |
Berlin A, Dal Pra A, Bristow RG. Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: Author reply British Journal of Radiology. 88. PMID 25363875 DOI: 10.1259/Bjr.20140701 |
0.513 |
|
| 2015 |
Ménard C, Iupati D, Publicover J, Lee J, Abed J, O'Leary G, Simeonov A, Foltz WD, Milosevic M, Catton C, Morton G, Bristow R, Bayley A, Atenafu EG, Evans AJ, et al. MR-guided prostate biopsy for planning of focal salvage after radiation therapy. Radiology. 274: 181-91. PMID 25203127 DOI: 10.1148/Radiol.14122681 |
0.447 |
|
| 2015 |
El Ghamrasni S, Cardoso R, Halaby MJ, Zeegers D, Harding S, Kumareswaran R, Yavorska T, Chami N, Jurisicova A, Sanchez O, Hande MP, Bristow R, Hakem R, Hakem A. Cooperation of Blm and Mus81 in development, fertility, genomic integrity and cancer suppression. Oncogene. 34: 1780-9. PMID 24858046 DOI: 10.1038/Onc.2014.121 |
0.618 |
|
| 2015 |
Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urologic Oncology. 33: 85-94. PMID 24768356 DOI: 10.1016/J.Urolonc.2013.10.020 |
0.691 |
|
| 2015 |
Fraser ME, Sabelnykova VY, Yamaguchi TN, Meng A, Heisler LE, Zhang J, Livingstone J, Huang V, Masella AP, Yousif F, Xie M, Harding NJ, Lin X, Kong H, Prokopec SD, ... ... Bristow RG, et al. Abstract 2966: The mutational landscape of localized gleason 6 and 7 prostate cancer Cancer Research. 75: 2966-2966. DOI: 10.1158/1538-7445.Am2015-2966 |
0.714 |
|
| 2015 |
Lo WW, Zafarana G, Bristow RG. Abstract 2214: Dynamic transcriptome analysis of DNA damage pathways under hypoxia Cancer Research. 75: 2214-2214. DOI: 10.1158/1538-7445.Am2015-2214 |
0.335 |
|
| 2015 |
Leão R, Castelo-Branco P, Lipman T, Campbell B, Price A, Zhang C, Buerno S, Gomes A, Coelho H, Bristow R, Schweiger M, Hamilton R, Zlotta A, Figueiredo A, Klocker H, et al. 422 TERT promoter methylation is a pan-cancer biomarker with prognostic significance in prostate cancer patients European Urology Supplements. 14: e422-e422a. DOI: 10.1016/S1569-9056(15)60415-8 |
0.405 |
|
| 2015 |
Risbridger G, Sliwinski A, Thorne H, Taylor R, Papargiris M, Hunter S, Campbell I, Thorne H, Li J, Mitchell G, Clouston D, Bristow R, Murphy D, Frydenberg M, Bolton D. 2569 Identifying high risk features and genomic instability in men with familial prostate cancer European Journal of Cancer. 51: S500-S501. DOI: 10.1016/S0959-8049(16)31388-0 |
0.486 |
|
| 2015 |
Castelo-Branco P, Leão R, De Mello R, Lipman T, Campbell B, Price A, Zhang C, Buerno S, Gomes A, Bristow R, Schweiger M, Hamilton R, Zlotta A, Figueiredo A, Klocker H, et al. 2503 Hypermethylation of a specific area in the TERT promoter defines a novel risk stratification biomarker for prostate cancer patients submitted to radical prostatectomy European Journal of Cancer. 51: S474. DOI: 10.1016/S0959-8049(16)31325-9 |
0.502 |
|
| 2015 |
Leao R, Castelo-Branco P, Lipman T, Campbell B, Price A, Zhang C, Gomes A, Coelho H, Bristow RG, Schweiger M, Hamilton RJ, Zlotta AR, Figueiredo A, Klocker H, Sulttmann H, et al. MP37-11 TERT PROMOTER METHYLATION IS A PAN-CANCER BIOMARKER WITH PROGNOSTIC SIGNIFICANCE IN PROSTATE CANCER PATIENTS Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1274 |
0.462 |
|
| 2015 |
Lo A, MacAulay C, Keyes M, Bristow R, Collins C, Fazli L, Gleave M, Guillaud M, Hayes M, Korbelik J, Palcic B. Evaluation of a Novel Quantitative Digital Pathology Technique as a Tool for Predicting Prostate Cancer Recurrence International Journal of Radiation Oncology*Biology*Physics. 93: E223. DOI: 10.1016/J.Ijrobp.2015.07.1110 |
0.364 |
|
| 2014 |
Zhukova N, Ramaswamy V, Remke M, Martin DC, Castelo-Branco P, Zhang CH, Fraser M, Tse K, Poon R, Shih DJ, Baskin B, Ray PN, Bouffet E, Dirks P, von Bueren AO, ... ... Bristow RG, et al. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications. 2: 174. PMID 25539912 DOI: 10.1186/S40478-014-0174-Y |
0.586 |
|
| 2014 |
Walker R, Louis A, Berlin A, Horsburgh S, Bristow RG, Trachtenberg J. Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 8: E783-8. PMID 25485004 DOI: 10.5489/Cuaj.1970 |
0.518 |
|
| 2014 |
Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, ... ... Bristow RG, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. The Lancet. Oncology. 15: 1521-32. PMID 25456371 DOI: 10.1016/S1470-2045(14)71021-6 |
0.719 |
|
| 2014 |
Berlin A, Lalonde E, Sykes J, Zafarana G, Chu KC, Ramnarine VR, Ishkanian A, Sendorek DH, Pasic I, Lam WL, Jurisica I, van der Kwast T, Milosevic M, Boutros PC, Bristow RG. NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. Oncotarget. 5: 11081-90. PMID 25415046 DOI: 10.18632/Oncotarget.2404 |
0.493 |
|
| 2014 |
Cui L, Tse K, Zahedi P, Harding SM, Zafarana G, Jaffray DA, Bristow RG, Allen C. Hypoxia and cellular localization influence the radiosensitizing effect of gold nanoparticles (AuNPs) in breast cancer cells. Radiation Research. 182: 475-88. PMID 25361396 DOI: 10.1667/Rr13642.1 |
0.608 |
|
| 2014 |
Kong V, Rosewall T, Chen S, Craig T, Bristow R, Milosevic M, Kwan M, Chung P. Deriving patient-specific planning target volume for partial bladder image guided radiation therapy. Practical Radiation Oncology. 4: 323-9. PMID 25194101 DOI: 10.1016/J.Prro.2013.10.005 |
0.326 |
|
| 2014 |
Chong LC, Albuquerque MA, Harding NJ, Caloian C, Chan-Seng-Yue M, de Borja R, Fraser M, Denroche RE, Beck TA, van der Kwast T, Bristow RG, McPherson JD, Boutros PC. SeqControl: process control for DNA sequencing. Nature Methods. 11: 1071-5. PMID 25173705 DOI: 10.1038/Nmeth.3094 |
0.575 |
|
| 2014 |
Chan N, Ali M, McCallum GP, Kumareswaran R, Koritzinsky M, Wouters BG, Wells PG, Gallinger S, Bristow RG. Hypoxia provokes base excision repair changes and a repair-deficient, mutator phenotype in colorectal cancer cells. Molecular Cancer Research : McR. 12: 1407-15. PMID 25030372 DOI: 10.1158/1541-7786.Mcr-14-0246 |
0.405 |
|
| 2014 |
Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Bristow R, Tolcher AW. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 74: 195-204. PMID 24849582 DOI: 10.1007/S00280-014-2481-1 |
0.304 |
|
| 2014 |
Shuhendler AJ, Prasad P, Zhang RX, Amini MA, Sun M, Liu PP, Bristow RG, Rauth AM, Wu XY. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Molecular Pharmaceutics. 11: 2659-74. PMID 24830351 DOI: 10.1021/Mp500093C |
0.308 |
|
| 2014 |
Boss MK, Bristow R, Dewhirst MW. Linking the History of Radiation Biology to the Hallmarks of Cancer Radiation Research. 181: 561-577. PMID 24811865 DOI: 10.1667/Rr13675.1 |
0.303 |
|
| 2014 |
Govind SK, Zia A, Hennings-Yeomans PH, Watson JD, Fraser M, Anghel C, Wyatt AW, van der Kwast T, Collins CC, McPherson JD, Bristow RG, Boutros PC. ShatterProof: operational detection and quantification of chromothripsis. Bmc Bioinformatics. 15: 78. PMID 24646301 DOI: 10.1186/1471-2105-15-78 |
0.594 |
|
| 2014 |
Bristow RG, Berlin A, Dal Pra A. An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy The British Journal of Radiology. 87: 20130753. PMID 24588670 DOI: 10.1259/Bjr.20130753 |
0.514 |
|
| 2014 |
Ramaekers CH, van den Beucken T, Bristow RG, Chiu RK, Durocher D, Wouters BG. RNF8-independent Lys63 poly-ubiquitylation prevents genomic instability in response to replication-associated DNA damage. Plos One. 9: e89997. PMID 24587176 DOI: 10.1371/Journal.Pone.0089997 |
0.321 |
|
| 2014 |
Miller JK, Buchner N, Timms L, Tam S, Luo X, Brown AM, Pasternack D, Bristow RG, Fraser M, Boutros PC, McPherson JD. Use of Sequenom sample ID Plus® SNP genotyping in identification of FFPE tumor samples. Plos One. 9: e88163. PMID 24551080 DOI: 10.1371/Journal.Pone.0088163 |
0.552 |
|
| 2014 |
Berlin A, Sykes J, Dal Pra A, Catton C, Van der Kwast T, Bristow RG. Prognostic utility of cell cycle progession score in men with prostate cancer after primary external beam radiation therapy. In regard to Freedland et al. International Journal of Radiation Oncology, Biology, Physics. 88: 237-40. PMID 24331671 DOI: 10.1016/J.Ijrobp.2013.10.009 |
0.438 |
|
| 2014 |
Shibata A, Moiani D, Arvai AS, Perry J, Harding SM, Genois MM, Maity R, van Rossum-Fikkert S, Kertokalio A, Romoli F, Ismail A, Ismalaj E, Petricci E, Neale MJ, Bristow RG, et al. DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. Molecular Cell. 53: 7-18. PMID 24316220 DOI: 10.1016/J.Molcel.2013.11.003 |
0.581 |
|
| 2014 |
Taiakina D, Dal Pra A, Bristow RG. Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. Advances in Experimental Medicine and Biology. 772: 189-204. PMID 24272360 DOI: 10.1007/978-1-4614-5915-6_9 |
0.562 |
|
| 2014 |
Milosevic MF, Pintilie M, Hedley DW, Bristow RG, Wouters BG, Oza AM, Laframboise S, Hill RP, Fyles AW. High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. International Journal of Cancer. Journal International Du Cancer. 135: 1692-9. PMID 23904154 DOI: 10.1002/Ijc.28403 |
0.37 |
|
| 2014 |
Lalani N, Richter S, Chung PWM, Fleshner NE, Jewett MA, Zlotta A, Bristow RG, Milosevic M, Sridhar SS. Concurrent cisplatin and radiotherapy: Decision making, tolerability, and outcomes for patients treated in a multidisciplinary bladder clinic. Journal of Clinical Oncology. 32: 320-320. DOI: 10.1200/Jco.2014.32.4_Suppl.320 |
0.337 |
|
| 2014 |
Berlin A, Lalonde E, Zafarana G, Sykes J, Ramnarine VR, Lam W, Meng A, Milosevic M, van der Kwast T, Boutros PC, Bristow RG. Using NBN to predict biochemical relapse following image-guided radiotherapy (IGRT) for intermediate-risk prostate cancer (IR-PCa). Journal of Clinical Oncology. 32: 26-26. DOI: 10.1200/Jco.2014.32.4_Suppl.26 |
0.54 |
|
| 2014 |
Hermanns T, Wei Y, Bindi B, Satkunasivam R, Athanasopoulos P, Bostrom P, Kuk C, Templeton A, Sridhar S, Van Der Kwast T, Chung P, Bristow R, Milosevic M, Fleshner N, Jewett M, et al. 793 A multidisciplinary bladder cancer clinic delivers personalized care for complex bladder cancer patients European Urology Supplements. 13: e793. DOI: 10.1016/S1569-9056(14)60781-8 |
0.373 |
|
| 2014 |
Gani C, Basler L, Ostafichuk D, Zafarana G, Bristow R. EP-1820: RAD17 and DNA replication as a potential target for improving radiotherapy in prostate cancer Radiotherapy and Oncology. 111: S296-S297. DOI: 10.1016/S0167-8140(15)31938-1 |
0.514 |
|
| 2014 |
Berlin A, Lalonde E, Zafarana G, Sykes J, Lam WL, Meng A, Milosevic M, Kwast TVd, Boutros PC, Bristow RG. PD-0300: NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer Radiotherapy and Oncology. 111. DOI: 10.1016/S0167-8140(15)30405-9 |
0.433 |
|
| 2014 |
Shibata A, Moiani D, Arvai AS, Perry J, Harding SM, Genois MM, Maity R, Rossum-Fikkert Sv, Kertokalio A, Romoli F, Ismail A, Ismalaj E, Petricci E, Neale MJ, Bristow RG, et al. Erratum DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities. [Molecular Cell 53, 9, (2014) 7-18] Molecular Cell. 53. DOI: 10.1016/J.Molcel.2014.01.008 |
0.566 |
|
| 2014 |
Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Boström PJ, Athanasopoulos P, Kuk C, Templeton AJ, Sridhar S, van der Kwast T, Chung P, Bristow RG, Milosevic M, Fleshner NE, Jewett MA, et al. MP65-01 PERSONALIZING BLADDER CANCER CARE: RESULTS OF A MULTIDISCIPLINARY BLADDER CANCER CLINIC Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1898 |
0.375 |
|
| 2014 |
Huang R, Vesprini D, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, Milosevic M, Warde P, Catton C. Long-Term Outcome of Dose Escalated Hypofractionated Intensity Modulated Radiation Therapy (IMRT) for Localized Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S421-S422. DOI: 10.1016/J.Ijrobp.2014.05.1336 |
0.443 |
|
| 2014 |
Zafarana G, Ishkanian A, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, Meng A, Ahmed O, Jurisca I, Milosevic M, Pintilie M, ... ... Bristow RG, et al. Erratum: Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy (Cancer (2012) 118 (4053-4062)) Cancer. 120. DOI: 10.1002/Cncr.28759 |
0.511 |
|
| 2013 |
Wang Q, Cui K, Espin-Garcia O, Cheng D, Qiu X, Chen Z, Moore M, Bristow RG, Xu W, Der S, Liu G. Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis. Plos One. 8: e82363. PMID 24349265 DOI: 10.1371/Journal.Pone.0082363 |
0.302 |
|
| 2013 |
Frame FM, Pellacani D, Collins AT, Simms MS, Mann VM, Jones GD, Meuth M, Bristow RG, Maitland NJ. HDAC inhibitor confers radiosensitivity to prostate stem-like cells. British Journal of Cancer. 109: 3023-33. PMID 24220693 DOI: 10.1038/Bjc.2013.691 |
0.508 |
|
| 2013 |
Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic instability. Genome Integrity. 4: 5. PMID 24152759 DOI: 10.1186/2041-9414-4-5 |
0.35 |
|
| 2013 |
Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, Bristow RG, Liu FF, Liu SK. miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Research. 73: 6972-86. PMID 24145350 DOI: 10.1158/0008-5472.Can-13-1657 |
0.336 |
|
| 2013 |
Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, ... ... Bristow RG, et al. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5202-9. PMID 23918607 DOI: 10.1158/1078-0432.Ccr-13-1049 |
0.496 |
|
| 2013 |
Segatto I, Berton S, Sonego M, Massarut S, D'Andrea S, Perin T, Fabris L, Armenia J, Rampioni G, Lovisa S, Schiappacassi M, Colombatti A, Bristow RG, Vecchione A, Baldassarre G, et al. Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. Journal of Molecular Cell Biology. 5: 428-31. PMID 23899505 DOI: 10.1093/Jmcb/Mjt027 |
0.311 |
|
| 2013 |
Sridharan S, Dal Pra A, Catton C, Bristow RG, Warde P. Locally advanced prostate cancer: Current controversies and optimisation opportunities Clinical Oncology. 25: 499-505. PMID 23680106 DOI: 10.1016/J.Clon.2013.04.004 |
0.502 |
|
| 2013 |
Trudel D, Zafarana G, Sykes J, Have CL, Bristow RG, van der Kwast T. 4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 61: 500-9. PMID 23640976 DOI: 10.1369/0022155413490946 |
0.456 |
|
| 2013 |
Liu TW, Macdonald TD, Jin CS, Gold JM, Bristow RG, Wilson BC, Zheng G. Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. Acs Nano. 7: 4221-32. PMID 23544841 DOI: 10.1021/Nn400669R |
0.522 |
|
| 2013 |
Dodbiba L, Teichman J, Fleet A, Thai H, Sun B, Panchal D, Patel D, Tse A, Chen Z, Faluyi OO, Renouf DJ, Girgis H, Bandarchi B, Schwock J, Xu W, ... Bristow RG, et al. Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Laboratory Investigation; a Journal of Technical Methods and Pathology. 93: 397-407. PMID 23399854 DOI: 10.1038/Labinvest.2013.8 |
0.386 |
|
| 2013 |
Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE. Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Research. 73: 1611-20. PMID 23302228 DOI: 10.1158/0008-5472.Can-12-1170 |
0.416 |
|
| 2013 |
Foltz WD, Wu A, Chung P, Catton C, Bayley A, Milosevic M, Bristow R, Warde P, Simeonov A, Jaffray DA, Haider MA, Ménard C. Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer. Journal of Magnetic Resonance Imaging : Jmri. 37: 909-16. PMID 23097411 DOI: 10.1002/Jmri.23885 |
0.467 |
|
| 2013 |
Cui L, Zahedi P, Saraceno J, Bristow R, Jaffray D, Allen C. Neoplastic cell response to tiopronin-coated gold nanoparticles. Nanomedicine : Nanotechnology, Biology, and Medicine. 9: 264-73. PMID 22687897 DOI: 10.1016/J.Nano.2012.05.016 |
0.307 |
|
| 2013 |
Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, ... ... Bristow R, et al. Targeting uroporphyrinogen decarboxylase for head and neck cancer treatment Bmc Proceedings. 7. DOI: 10.1186/1753-6561-7-S2-P19 |
0.385 |
|
| 2013 |
Fraser ME, Borja Rd, Trudel D, Harding NJ, Hennings-Yeomans PH, Meng A, Lalonde ER, Brown A, Fox NS, Chong T, Zia A, Sam M, Wang J, Chan-Seng-Yue MA, Johns J, ... ... Bristow RG, et al. Abstract 2003: A molecular portrait of potentially curable prostate cancer. Cancer Research. 73: 2003-2003. DOI: 10.1158/1538-7445.Am2013-2003 |
0.693 |
|
| 2013 |
Lalonde E, Boutros PC, Fraser M, Borja Rd, Harding NJ, Trudel D, Meng A, Hennings-Yeomans PH, McPherson A, Zia A, Wang J, Beck T, Fox NS, Chong T, Sam M, ... ... Bristow RG, et al. Abstract B129: Clinical implications of inter- and intra- prostatic heterogeneity. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B129 |
0.718 |
|
| 2013 |
Liu TW, MacDonald TD, Jin CS, Gold JM, Bristow RG, Wilson BC, Zheng G. Correction to Inherently Multimodal Nanoparticle-Driven Tracking and Real-Time Delineation of Orthotopic Prostate Tumors and Micrometastases Acs Nano. 7: 4691-4691. DOI: 10.1021/Nn401788G |
0.39 |
|
| 2013 |
Boutros P, Lalonde E, Ishkanian A, Sykes J, Moon N, Zafarana G, Thoms J, Have L, Malloff C, Ramnarine V, Meng A, Mak D, Squire J, Jurisica I, Pintilie M, ... ... Bristow R, et al. MC13-0009 A prognostic CNA signature sub-stratifies intermediate-risk prostate cancer European Journal of Cancer. 49: S14. DOI: 10.1016/S0959-8049(13)70127-8 |
0.504 |
|
| 2013 |
Dal Pra A, Zannella V, Glicksman R, Sykes J, Muaddi H, Joshua A, Wouters B, Milosevic M, Koritzinsky M, Bristow R. Metformin and Prostate Cancer Radiation Therapy: Improved Outcomes Due to Enhanced Tumor Oxygenation International Journal of Radiation Oncology*Biology*Physics. 87: S170. DOI: 10.1016/J.Ijrobp.2013.06.440 |
0.475 |
|
| 2013 |
Fotouhi Ghiam A, Zafarana G, Emilie L, Sykes J, Lam W, Meng A, Boutros P, Milosevic M, van der Kwast T, Bristow R. Genomic Instability in Common Fragile Sites (CFSs) Is Associated With Less Favorable Outcome in Patients With Intermediate-Risk Prostate Cancer (IR-CaP) International Journal of Radiation Oncology*Biology*Physics. 87: S124. DOI: 10.1016/J.Ijrobp.2013.06.321 |
0.494 |
|
| 2013 |
Fraser M, Berlin A, Ouellet V, Saad F, Bristow RG. Prostate Cancer Genomics as a Driver of Personalized Medicine Cancer Genomics: From Bench to Personalized Medicine. 233-245. DOI: 10.1016/B978-0-12-396967-5.00014-1 |
0.68 |
|
| 2012 |
Tolan SP, Thoms J, Dal Pra A, Ahmed O, Chung PW, Warde F, Zlotta A, Evans A, Bristow RG, Milosevic M. Association of tumor hypoxia with lower survival after radiotherapy for muscle-invasive bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 292. PMID 27968105 DOI: 10.1200/Jco.2012.30.5_Suppl.292 |
0.334 |
|
| 2012 |
Dal Pra A, Warde F, Ishkanian AS, Meng A, Malloff C, Lam W, Sykes J, Pintile M, Squire J, van der Kwast T, Evans A, Milosevic M, Bristow RG. TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 11. PMID 27967837 DOI: 10.1200/Jco.2012.30.5_Suppl.11 |
0.524 |
|
| 2012 |
McKee CM, Xu D, Cao Y, Kabraji S, Allen D, Kersemans V, Beech J, Smart S, Hamdy F, Ishkanian A, Sykes J, Pintile M, Milosevic M, van der Kwast T, Zafarana G, ... ... Bristow RG, et al. Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. The Journal of Clinical Investigation. 122: 4025-36. PMID 23041623 DOI: 10.1172/Jci59348 |
0.443 |
|
| 2012 |
Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M, Catton C, Pintilie M, Chambers AF, Bristow RG. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. British Journal of Cancer. 107: 840-6. PMID 22871886 DOI: 10.1038/Bjc.2012.345 |
0.463 |
|
| 2012 |
Raghavan P, Tumati V, Yu L, Chan N, Tomimatsu N, Burma S, Bristow RG, Saha D. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. International Journal of Radiation Oncology, Biology, Physics. 84: e507-14. PMID 22795803 DOI: 10.1016/J.Ijrobp.2012.05.035 |
0.333 |
|
| 2012 |
Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R, Loblaw A, Narod SA, Nam RK. Association between germline HOXB13 G84E mutation and risk of prostate cancer. Journal of the National Cancer Institute. 104: 1260-2. PMID 22781434 DOI: 10.1093/Jnci/Djs288 |
0.487 |
|
| 2012 |
Luo T, Yu J, Nguyen J, Wang CR, Bristow RG, Jaffray DA, Zhou XZ, Lu KP, Lu QB. Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. Proceedings of the National Academy of Sciences of the United States of America. 109: 10175-80. PMID 22685209 DOI: 10.1073/Pnas.1203451109 |
0.389 |
|
| 2012 |
Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, ... ... Bristow RG, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. The Journal of Pathology. 227: 286-97. PMID 22553170 DOI: 10.1002/Path.4047 |
0.519 |
|
| 2012 |
Milosevic M, Warde P, Ménard C, Chung P, Toi A, Ishkanian A, McLean M, Pintilie M, Sykes J, Gospodarowicz M, Catton C, Hill RP, Bristow R. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2108-14. PMID 22465832 DOI: 10.1158/1078-0432.CCR-11-2711 |
0.421 |
|
| 2012 |
Harding SM, Bristow RG. Discordance between phosphorylation and recruitment of 53BP1 in response to DNA double-strand breaks. Cell Cycle (Georgetown, Tex.). 11: 1432-44. PMID 22421153 DOI: 10.4161/Cc.19824 |
0.598 |
|
| 2012 |
Van Der Kwast T, Al Daoud N, Collette L, Sykes J, Thoms J, Milosevic M, Bristow RG, Van Tienhoven G, Warde P, Mirimanoff RO, Bolla M. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy European Journal of Cancer. 48: 1318-1325. PMID 22405699 DOI: 10.1016/J.Ejca.2012.02.003 |
0.459 |
|
| 2012 |
Dal Pra A, Milosevic M, Hill R, Wouters B, Warde P, Bristow RG. Hypoxia, androgen deprivation and systemic metastases in prostate cancer (in response to "Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxitivity dynamic MRI": in regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3):721-727). International Journal of Radiation Oncology, Biology, Physics. 82: 1319. PMID 22385713 DOI: 10.1016/J.Ijrobp.2011.11.017 |
0.487 |
|
| 2012 |
Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmbhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, ... ... Bristow RG, et al. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. The Journal of Pathology. 227: 53-61. PMID 22294438 DOI: 10.1002/Path.3987 |
0.481 |
|
| 2012 |
Chopra S, Toi A, Taback N, Evans A, Haider MA, Milosevic M, Bristow RG, Chung P, Bayley A, Morton G, Vesprini D, Warde P, Catton C, Ménard C. Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 82: e441-8. PMID 22284038 DOI: 10.1016/J.Ijrobp.2011.05.035 |
0.48 |
|
| 2012 |
Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Jurisca I, Milosevic M, ... ... Bristow RG, et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer. 118: 4053-62. PMID 22281794 DOI: 10.1002/Cncr.26729 |
0.492 |
|
| 2012 |
Kumareswaran R, Ludkovski O, Meng A, Sykes J, Pintilie M, Bristow RG. Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. Journal of Cell Science. 125: 189-99. PMID 22266907 DOI: 10.1242/Jcs.092262 |
0.321 |
|
| 2012 |
Sanli T, Storozhuk Y, Linher-Melville K, Bristow RG, Laderout K, Viollet B, Wright J, Singh G, Tsakiridis T. Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 102: 459-65. PMID 22225791 DOI: 10.1016/J.Radonc.2011.11.014 |
0.346 |
|
| 2012 |
Locke JA, Zafarana G, Malloff CA, Lam WL, Sykes J, Pintilie M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Guns ET, van der Kwast T, Milosevic M, Bristow RG. Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. The Prostate. 72: 1295-305. PMID 22213075 DOI: 10.1002/Pros.22478 |
0.455 |
|
| 2012 |
Ghiam AF, Cairns RA, Thoms J, Dal Pra A, Ahmed O, Meng A, Mak TW, Bristow RG. IDH mutation status in prostate cancer Oncogene. 31: 3826. PMID 22120718 DOI: 10.1038/Onc.2011.546 |
0.426 |
|
| 2012 |
Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1015-27. PMID 22114138 DOI: 10.1158/1078-0432.Ccr-11-2189 |
0.714 |
|
| 2012 |
Vesprini D, Catton C, Jacks L, Lockwood G, Rosewall T, Bayley A, Chung P, Gospodarowicz M, Ménard C, Milosevic M, Nichol A, Skala M, Warde P, Bristow RG. Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 83: 608-16. PMID 22099034 DOI: 10.1016/J.Ijrobp.2011.07.019 |
0.519 |
|
| 2012 |
Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, Malloff CA, Lam WL, Squire JA, Pintilie M, Sykes J, Ramnarine VR, Meng A, Ahmed O, Jurisica I, ... ... Bristow RG, et al. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 308-16. PMID 22048240 DOI: 10.1158/1078-0432.Ccr-11-2147 |
0.551 |
|
| 2012 |
Zhukova N, Martin D, Lipman T, Castelo-Branco P, Zhang CH, Fraser M, Baskin B, Ray P, Bouffet E, Bristow R, Alman BA, Taylor MD, Malkin D, Hawkins C, Tabori U. Abstract LB-210: Abrogation of mutant TP53 radiation resistance by lithium induced CTNNB1 (β-catenin) activation in medulloblastoma. Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-210 |
0.603 |
|
| 2012 |
Sam MR, Chong T, Zia A, Lalonde E, Yousif F, Denroche R, Chan-Seng-Yue M, Meng A, Fraser M, Johns J, Timms L, Borja Rd, Starmans MHW, Wang J, Hennings-Yeomans P, ... ... Bristow RG, et al. Abstract 3184: Whole genome sequencing of low-input fresh frozen prostate cancer biopsies Cancer Research. 72: 3184-3184. DOI: 10.1158/1538-7445.Am2012-3184 |
0.691 |
|
| 2012 |
McKee C, Xu D, Kabraji S, Allen D, Kersemans V, Beech J, Smart S, Hamdy F, Lam W, Kwast Tvd, Bristow R, Muschel R. Abstract 2463: Protease nexin 1 modulates prostate adenocarcinoma by regulating the Hedgehog pathway in humans and mice Cancer Research. 72: 2463-2463. DOI: 10.1158/1538-7445.Am2012-2463 |
0.502 |
|
| 2012 |
Bostrom PJ, Thoms J, van Rhijn BW, Ahmed O, Stakhovskyi O, Margel D, Evans A, Mirtti T, Sykes J, Pintillie M, Laato M, Milosevic M, Zlotta AR, Bristow RG. 1417 HYPOXIA IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOME IN UROTHELIAL BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY Journal of Urology. 187. DOI: 10.1016/S1569-9056(12)60902-6 |
0.329 |
|
| 2012 |
Bristow R, Kumareswaran R, Harding S, Chan N. SP-0029 EXPLOITING HYPOXIA DEPENDENT DNA REPAIR DEFECTS Radiotherapy and Oncology. 103: S11. DOI: 10.1016/S0167-8140(12)70368-7 |
0.531 |
|
| 2012 |
Bostrom PJ, Thoms J, Rhijn BWGv, Ahmed O, Stakhovskyi O, Margel D, Evans A, Mirtti T, Sykes J, Pintillie M, Laato M, Milosevic M, Zlotta AR, Bristow RG. Bladder Cancer: Invasive IModerated Poster1417 HYPOXIA IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOME IN UROTHELIAL BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1868 |
0.402 |
|
| 2012 |
Van der Kwast T, Al Daoud N, Collette L, Sykes J, Thoms J, Milosevic M, Bristow R, Van Tienhoven G, Warde P, Mirimanoff R, Bolla M. Corrigendum to: “Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy” [Eur J Cancer 2012;48(9): 1318–25] European Journal of Cancer. 48: 2292. DOI: 10.1016/J.Ejca.2012.07.001 |
0.508 |
|
| 2011 |
Iupati D, Haider MA, Chung PW, Bayley A, Catton C, Milosevic M, Bristow RG, Morton G, Warde PR, Menard C. Can MRI accurately define tumor boundaries to guide focal salvage after radiotherapy? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 124. PMID 27968537 DOI: 10.1200/Jco.2011.29.7_Suppl.124 |
0.446 |
|
| 2011 |
Bristow RG, Ishkanian AS, Malloff C, Milosevic M, Pintilie M, van der Kwast T, Lam W. Use of genetic instability to predict biochemical recurrence in intermediate-risk prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 42. PMID 27968410 DOI: 10.1200/Jco.2011.29.7_Suppl.42 |
0.503 |
|
| 2011 |
Milosevic M, Bristow RG, Menard C, Chung PW, Bayley A, McLean M, Toi A, Gospodarowicz MK, Catton C, Warde PR. Prostate cancer hypoxia as a predictor of early biochemical and local failure after radiotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 20. PMID 27968387 DOI: 10.1200/Jco.2011.29.7_Suppl.20 |
0.525 |
|
| 2011 |
Rashid A, Liu C, Sanli T, Tsiani E, Singh G, Bristow RG, Dayes I, Lukka H, Wright J, Tsakiridis T. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiation Oncology (London, England). 6: 144. PMID 22029423 DOI: 10.1186/1748-717X-6-144 |
0.455 |
|
| 2011 |
Zhao H, Luoto KR, Meng AX, Bristow RG. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 101: 59-65. PMID 21903282 DOI: 10.1016/J.Radonc.2011.08.013 |
0.305 |
|
| 2011 |
Glazer PM, Le QT, Bristow R, Helleday T, Pelroy R, Bernhard EJ. New translational possibilities for microenvironmental modulation of radiosensitivity Radiation Research. 176: 412-414. PMID 21867431 DOI: 10.1667/Rrxx33.1 |
0.362 |
|
| 2011 |
Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ. Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010. Radiation Research. 176: e0016-21. PMID 21867428 DOI: 10.1667/Rrol02.1 |
0.346 |
|
| 2011 |
Mothersill C, Bristow RG, Harding SM, Smith RW, Mersov A, Seymour CB. A role for p53 in the response of bystander cells to receipt of medium borne signals from irradiated cells. International Journal of Radiation Biology. 87: 1120-5. PMID 21831006 DOI: 10.3109/09553002.2011.610866 |
0.558 |
|
| 2011 |
Ramaekers CH, van den Beucken T, Meng A, Kassam S, Thoms J, Bristow RG, Wouters BG. Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 101: 190-7. PMID 21722982 DOI: 10.1016/J.Radonc.2011.05.059 |
0.344 |
|
| 2011 |
Harding SM, Coackley C, Bristow RG. ATM-dependent phosphorylation of 53BP1 in response to genomic stress in oxic and hypoxic cells. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 99: 307-12. PMID 21680038 DOI: 10.1016/J.Radonc.2011.05.039 |
0.581 |
|
| 2011 |
Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle (Georgetown, Tex.). 10: 2218-32. PMID 21623170 DOI: 10.4161/Cc.10.13.16305 |
0.714 |
|
| 2011 |
Tolan S, Kong V, Rosewall T, Craig T, Bristow R, Milosevic M, Gospodarowicz M, Chung P. Patient-specific PTV margins in radiotherapy for bladder cancer - a feasibility study using cone beam CT. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 99: 131-6. PMID 21620497 DOI: 10.1016/J.Radonc.2011.04.008 |
0.318 |
|
| 2011 |
Dent RA, Bristow RG. In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2130-2. PMID 21519017 DOI: 10.1200/Jco.2010.34.1990 |
0.334 |
|
| 2011 |
Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 81: e415-21. PMID 21477939 DOI: 10.1016/J.Ijrobp.2011.01.024 |
0.431 |
|
| 2011 |
Vesprini D, Narod SA, Trachtenberg J, Crook J, Jalali F, Preiner J, Sridhar S, Bristow RG. The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 5: E31-5. PMID 21470549 DOI: 10.5489/Cuaj.10080 |
0.475 |
|
| 2011 |
Al Rashid ST, Harding SM, Law C, Coackley C, Bristow RG. Protein-protein interactions occur between p53 phosphoforms and ATM and 53BP1 at sites of exogenous DNA damage. Radiation Research. 175: 588-98. PMID 21361779 DOI: 10.1667/Rr2084.1 |
0.577 |
|
| 2011 |
Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, ... ... Bristow R, et al. Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Science Translational Medicine. 3: 67ra7. PMID 21270338 DOI: 10.1126/Scitranslmed.3001922 |
0.41 |
|
| 2011 |
Thoms J, Goda JS, Zlotta AR, Fleshner NE, van der Kwast TH, Supiot S, Warde P, Bristow RG. Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nature Reviews. Clinical Oncology. 8: 107-13. PMID 21178999 DOI: 10.1038/Nrclinonc.2010.207 |
0.454 |
|
| 2011 |
Sia M, Rodrigues G, Menard C, Bayley A, Bristow R, Chung P, Gospodarowicz M, Milosevic M, Warde P, Catton C. Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 4: 105-11. PMID 20368892 DOI: 10.5489/Cuaj.801 |
0.475 |
|
| 2011 |
Teichman J, Dodbiba L, Bristow R, Liu G, Allies L. Abstract B49: Using ionizing radiation and primary human esophageal adenocarcinoma xenograft models to interrogate tumor cell characteristics associated with tumor-initiating cells Stem Cells. 71. DOI: 10.1158/1538-7445.Fbcr11-B49 |
0.304 |
|
| 2011 |
Tse KCK, Harding SM, Zafarana G, Ahmed K, Dellaire G, Bazett-Jones D, Bristow RG. Abstract 3916: PML nuclear bodies are juxtaposed to DNA-DSBs following IR-induced DNA damage Cancer Research. 71: 3916-3916. DOI: 10.1158/1538-7445.Am2011-3916 |
0.351 |
|
| 2011 |
Bristow R. 209 INVITED Personalized Medicine and Prostate Cancer Radiotherapy European Journal of Cancer. 47: S49. DOI: 10.1016/S0959-8049(11)70424-5 |
0.414 |
|
| 2011 |
Mok G, Martin J, Massey C, Bayley A, Menard C, Chung P, Bristow R, Warde P, Gospodarowicz M, Catton C. A Comparison of Conventional and Hypofractionated Radiotherapy Schedules In the Treatment of Localized Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 81: S401-S402. DOI: 10.1016/J.Ijrobp.2011.06.648 |
0.507 |
|
| 2010 |
O'Donnell L, Panier S, Wildenhain J, Tkach JM, Al-Hakim A, Landry MC, Escribano-Diaz C, Szilard RK, Young JT, Munro M, Canny MD, Kolas NK, Zhang W, Harding SM, Ylanko J, ... ... Bristow RG, et al. The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination. Molecular Cell. 40: 619-31. PMID 21055983 DOI: 10.1016/J.Molcel.2010.10.024 |
0.575 |
|
| 2010 |
Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, Bristow RG. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Research. 70: 8748-59. PMID 20940401 DOI: 10.1158/0008-5472.Can-10-0944 |
0.358 |
|
| 2010 |
Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, Helleday T, Hammond EM, Bristow RG. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Research. 70: 8045-54. PMID 20924112 DOI: 10.1158/0008-5472.Can-10-2352 |
0.366 |
|
| 2010 |
Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF, Elliott F, Lowery J, Taylor CF, Churchman M, Bentley J, Knowles MA, Harnden P, Bristow RG, Bishop DT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Research. 70: 7017-26. PMID 20843819 DOI: 10.1158/0008-5472.Can-10-1202 |
0.427 |
|
| 2010 |
Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Seminars in Radiation Oncology. 20: 274-81. PMID 20832020 DOI: 10.1016/J.Semradonc.2010.06.001 |
0.358 |
|
| 2010 |
Thoms J, Bristow RG. DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Seminars in Radiation Oncology. 20: 217-22. PMID 20832013 DOI: 10.1016/J.Semradonc.2010.06.003 |
0.331 |
|
| 2010 |
Bristow RG. Introduction: DNA repair and radiotherapy targeting: an overview. Seminars in Radiation Oncology. 20: 215-6. PMID 20832012 DOI: 10.1016/J.Semradonc.2010.06.002 |
0.303 |
|
| 2010 |
Chan N, Bristow RG. "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4553-60. PMID 20823145 DOI: 10.1158/1078-0432.Ccr-10-0527 |
0.336 |
|
| 2010 |
Zafarana G, Bristow RG. Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie! Breast Cancer Research : Bcr. 12: 111. PMID 20619004 DOI: 10.1186/Bcr2597 |
0.372 |
|
| 2010 |
Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J, Tsakiridis T. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. International Journal of Radiation Oncology, Biology, Physics. 78: 221-9. PMID 20615625 DOI: 10.1016/J.Ijrobp.2010.03.005 |
0.611 |
|
| 2010 |
Ishkanian AS, Zafarana G, Thoms J, Bristow RG. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncologica (Stockholm, Sweden). 49: 888-94. PMID 20590366 DOI: 10.3109/0284186X.2010.499371 |
0.573 |
|
| 2010 |
Li L, Halaby MJ, Hakem A, Cardoso R, El Ghamrasni S, Harding S, Chan N, Bristow R, Sanchez O, Durocher D, Hakem R. Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. The Journal of Experimental Medicine. 207: 983-97. PMID 20385750 DOI: 10.1084/Jem.20092437 |
0.616 |
|
| 2010 |
Thoms J, Bristow R, Warde P, Supiot S. Response to "Intraoperative Radiotherapy During Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical and Dosimetric Aspects" (Int J Radiat Oncol Biol Phys 2009; in press) International Journal of Radiation Oncology Biology Physics. 76: 1277. PMID 20206029 DOI: 10.1016/J.Ijrobp.2009.11.050 |
0.499 |
|
| 2010 |
Kato H, Ito E, Shi W, Alajez NM, Yue S, Lee C, Chan N, Bhogal N, Coackley CL, Vines D, Green D, Waldron J, Gullane P, Bristow R, Liu FF. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 898-911. PMID 20103674 DOI: 10.1158/1078-0432.Ccr-09-1945 |
0.354 |
|
| 2010 |
Tabassum A, Bristow RG, Venkateswaran V. Ingestion of selenium and other antioxidants during prostate cancer radiotherapy: a good thing? Cancer Treatment Reviews. 36: 230-4. PMID 20079573 DOI: 10.1016/J.Ctrv.2009.12.008 |
0.516 |
|
| 2010 |
Nichol AM, Warde PR, Lockwood GA, Kirilova AK, Bayley A, Bristow R, Crook J, Gospodarowicz M, McLean M, Milosevic M, Rosewall T, Jaffray DA, Catton CN. A cinematic magnetic resonance imaging study of milk of magnesia laxative and an antiflatulent diet to reduce intrafraction prostate motion. International Journal of Radiation Oncology, Biology, Physics. 77: 1072-8. PMID 19783378 DOI: 10.1016/J.Ijrobp.2009.06.005 |
0.34 |
|
| 2010 |
Bayley A, Rosewall T, Craig T, Bristow R, Chung P, Gospodarowicz M, Ménard C, Milosevic M, Warde P, Catton C. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics. 77: 477-483. PMID 19733014 DOI: 10.1016/J.Ijrobp.2009.05.006 |
0.401 |
|
| 2010 |
Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, ... ... Bristow R, et al. Abstract SSY01-03: An RNAi screen identifies a heme biosynthetic mediator as a novel radiosensitizing target for head and neck cancer Tumor Biology. DOI: 10.1158/1538-7445.Am10-Ssy01-03 |
0.321 |
|
| 2010 |
Fraser ME, Zhao H, Lundin C, Evans A, Helleday T, Bristow RG. Abstract 3932: Loss of PTEN sensitizes cells to DNA damaging agents in a RAD51-independent manner Cancer Research. 70: 3932-3932. DOI: 10.1158/1538-7445.Am10-3932 |
0.681 |
|
| 2010 |
Zafarana G, Ishkanian A, Maloff C, Thoms J, Squire J, Pintile M, Milosevic M, Lam W, Kvast Tvd, Bristow RG. Abstract 2136: Combined 8q gain and 10q loss predicts for relapse following radical radiotherapy in intermediate risk prostate cancer Cancer Research. 70: 2136-2136. DOI: 10.1158/1538-7445.Am10-2136 |
0.535 |
|
| 2010 |
Li L, Halaby M, Hakem A, Cardoso R, El Ghamrasni S, Harding S, Chan N, Bristow R, Sanchez O, Durocher D, Hakem R. Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer The Journal of Cell Biology. 189: i6-i6. DOI: 10.1083/JCB1892OIA6 |
0.549 |
|
| 2010 |
Keller H, Vines D, Lakshman M, Dunne M, Lindsay P, Green D, Clarkson R, Bristow R. 106 poster: Characterization of Flt-Pet Response to High- and Low-Dose Radiation of a Lung Cancer Xenograft in Mice Radiotherapy and Oncology. 94: S41-S42. DOI: 10.1016/S0167-8140(15)34525-4 |
0.315 |
|
| 2010 |
Ishkanian A, Malloff C, Meng A, Zafarana G, Albert M, Pintile M, van der Kwast T, Milosevic M, Lam W, Bristow R. DNA Copy Number Alterations Independently Predict for Biochemical Recurrence following Radiotherapy in Intermediate Risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 78: S26. DOI: 10.1016/J.Ijrobp.2010.07.101 |
0.528 |
|
| 2009 |
Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, Milosevic M, Rosewall T, Warde PR, Catton CN. Image guided dose escalated prostate radiotherapy: still room to improve. Radiation Oncology (London, England). 4: 50. PMID 19887007 DOI: 10.1186/1748-717X-4-50 |
0.435 |
|
| 2009 |
Bristow RG. IMRT and molecular biological approaches in radiotherapy for prostate cancer. European Journal of Cancer (Oxford, England : 1990). 45: 429-30. PMID 19775659 DOI: 10.1016/S0959-8049(09)70077-2 |
0.513 |
|
| 2009 |
Chopra S, Foltz WD, Milosevic MF, Toi A, Bristow RG, Ménard C, Haider MA. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. International Journal of Radiation Biology. 85: 805-13. PMID 19728195 DOI: 10.1080/09553000903043059 |
0.399 |
|
| 2009 |
Christensen E, Pintilie M, Evans KR, Lenarduzzi M, Ménard C, Catton CN, Diamandis EP, Bristow RG. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5576-83. PMID 19706801 DOI: 10.1158/1078-0432.Ccr-09-0245 |
0.486 |
|
| 2009 |
Wiltshire KL, Laperriere N, Bristow RG. Prolonged survival in a patient with choroidal metastases from urothelial bladder cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 3: E36-E38. PMID 19672435 DOI: 10.5489/Cuaj.1138 |
0.345 |
|
| 2009 |
Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. International Journal of Radiation Oncology, Biology, Physics. 74: 1580-91. PMID 19540073 DOI: 10.1016/J.Ijrobp.2009.03.047 |
0.313 |
|
| 2009 |
Chan N, Koch CJ, Bristow RG. Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Current Molecular Medicine. 9: 401-10. PMID 19519397 DOI: 10.2174/156652409788167050 |
0.322 |
|
| 2009 |
Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire JA, Lam WL, Bristow RG. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. The Prostate. 69: 1091-100. PMID 19350549 DOI: 10.1002/Pros.20959 |
0.445 |
|
| 2009 |
Woodward WA, Bristow RG. Radiosensitivity of Cancer-Initiating Cells and Normal Stem Cells (or what the Heisenberg Uncertainly Principle has to do with Biology) Seminars in Radiation Oncology. 19: 87-95. PMID 19249646 DOI: 10.1016/J.Semradonc.2008.11.003 |
0.423 |
|
| 2009 |
Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, Haile R, Hopper JL, LeMarchand L, Lindor N, Parfrey P, Potter J, Younghusband B, Gallinger S. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology. 136: 1251-60. PMID 19245865 DOI: 10.1053/J.Gastro.2008.12.050 |
0.362 |
|
| 2009 |
Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, Kiltie AE, Bristow RG. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Molecular Cancer Therapeutics. 8: 203-13. PMID 19139130 DOI: 10.1158/1535-7163.Mct-08-0959 |
0.376 |
|
| 2009 |
Martin JM, Bayley A, Bristow R, Chung P, Gospodarowicz M, Menard C, Milosevic M, Rosewall T, Warde PR, Catton CN. Correction: Image guided dose escalated prostate radiotherapy: still room to improve Radiation Oncology. 4: 65-65. DOI: 10.1186/1748-717X-4-65 |
0.379 |
|
| 2009 |
Bristow RG, Zhao H, Fraser M. Abstract A122: The tyrosine kinase inhibitor MP470 inhibits RAD51‐mediated homologous recombination and increases tumor cell radio‐ and chemosensitivity Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A122 |
0.613 |
|
| 2009 |
Chan N, Pires IM, Bencokova Z, Coackley C, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, Helleday T, Hammond EM, Bristow RG. Abstract A115: Contextual synthetic lethality: Repair‐deficient hypoxic tumor cells are sensitized to poly(ADP‐ribose) polymerase (PARP) inhibition Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A115 |
0.343 |
|
| 2009 |
Chopra S, Toi A, Haider M, Milosevic M, Bristow R, Bayley A, Chung P, Vesprini D, Morton G, Catton C, Warde P, Gospodarowicz M, Menard C. 68 SPATIAL PATTERNS OF LOCAL RECURRENCE AFTER RADIOTHERAPY FOR PROSTATE CANCER Radiotherapy and Oncology. 92: S22. DOI: 10.1016/S0167-8140(12)72455-6 |
0.478 |
|
| 2009 |
Milosevic M, Bristow R, Ménard C, Panzarella T, Chung P, Toi A, Warde P, Catton C, Hill R. Hypoxia is Associated with Early Biochemical Failure after Radiotherapy in Patients with Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 75: S105. DOI: 10.1016/J.Ijrobp.2009.07.255 |
0.507 |
|
| 2008 |
Gevorgyan A, Sukhu B, Alman BA, Bristow RG, Pang CY, Forrest CR. Radiation effects and radioprotection in MC3T3-E1 mouse calvarial osteoblastic cells. Plastic and Reconstructive Surgery. 122: 1025-35. PMID 18827633 DOI: 10.1097/Prs.0B013E3181845931 |
0.303 |
|
| 2008 |
Choudhury A, Elliott F, Iles MM, Churchman M, Bristow RG, Bishop DT, Kiltie AE. Analysis of variants in DNA damage signalling genes in bladder cancer. Bmc Medical Genetics. 9: 69. PMID 18638378 DOI: 10.1186/1471-2350-9-69 |
0.355 |
|
| 2008 |
Ali M, Kim H, Cleary S, Cupples C, Gallinger S, Bristow R. Characterization of mutant MUTYH proteins associated with familial colorectal cancer. Gastroenterology. 135: 499-507. PMID 18534194 DOI: 10.1053/J.Gastro.2008.04.035 |
0.326 |
|
| 2008 |
Liu SK, Olive PL, Bristow RG. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Reviews. 27: 445-58. PMID 18516501 DOI: 10.1007/S10555-008-9137-8 |
0.38 |
|
| 2008 |
Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 88: 258-68. PMID 18456354 DOI: 10.1016/J.Radonc.2008.04.005 |
0.409 |
|
| 2008 |
Christensen E, Evans KR, Ménard C, Pintilie M, Bristow RG. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer Metastasis Reviews. 27: 375-85. PMID 18427732 DOI: 10.1007/S10555-008-9139-6 |
0.485 |
|
| 2008 |
Supiot S, Shubbar S, Fleshner N, Warde P, Hersey K, Wallace K, Cole H, Sweet J, Tsihlias J, Jewett MA, Klotz L, Bristow RG. A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 88: 53-60. PMID 18423916 DOI: 10.1016/J.Radonc.2008.03.019 |
0.48 |
|
| 2008 |
Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Molecular Cancer Therapeutics. 7: 993-9. PMID 18413812 DOI: 10.1158/1535-7163.Mct-07-0442 |
0.388 |
|
| 2008 |
Cuddihy AR, Jalali F, Coackley C, Bristow RG. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Molecular Cancer Therapeutics. 7: 980-92. PMID 18413811 DOI: 10.1158/1535-7163.Mct-07-0471 |
0.355 |
|
| 2008 |
Rosewall T, Chung P, Bayley A, Lockwood G, Alasti H, Bristow R, Kong V, Milosevic M, Catton C. A randomized comparison of interfraction and intrafraction prostate motion with and without abdominal compression. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 88: 88-94. PMID 18279985 DOI: 10.1016/J.Radonc.2008.01.019 |
0.376 |
|
| 2008 |
Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature Reviews. Cancer. 8: 180-92. PMID 18273037 DOI: 10.1038/Nrc2344 |
0.325 |
|
| 2008 |
Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 86: 407-11. PMID 18237796 DOI: 10.1016/J.Radonc.2008.01.001 |
0.502 |
|
| 2008 |
Sarkaria JN, Bristow RG. Overview of cancer molecular radiobiology. Cancer Treatment and Research. 139: 117-33. PMID 18236714 DOI: 10.1007/978-0-387-36744-6_6 |
0.381 |
|
| 2008 |
Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B, Bristow RG. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Research. 68: 605-14. PMID 18199558 DOI: 10.1158/0008-5472.Can-07-5472 |
0.332 |
|
| 2008 |
Chopra S, Menard C, Bristow R, Toi A, Milosevic M, Haider M. Correlation of BOLD MRI with measures of tumor hypoxia in prostate cancer RöFo - Fortschritte Auf Dem Gebiet Der RöNtgenstrahlen Und Der Bildgebenden Verfahren. 180. DOI: 10.1055/s-0028-1085911 |
0.387 |
|
| 2007 |
Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, Catton CN, McLean M, Moore M, Tannock IF, Gospodarowicz MK. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urologic Oncology. 25: 303-9. PMID 17628296 DOI: 10.1016/J.Urolonc.2006.09.015 |
0.388 |
|
| 2007 |
Milosevic M, Chung P, Parker C, Bristow R, Toi A, Panzarella T, Warde P, Catton C, Menard C, Bayley A, Gospodarowicz M, Hill R. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Research. 67: 6022-5. PMID 17616657 DOI: 10.1158/0008-5472.Can-07-0561 |
0.511 |
|
| 2007 |
Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M, McLean M, Ménard C, Milosevic M, Warde P, Catton C. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics. 69: 1084-9. PMID 17606331 DOI: 10.1016/J.Ijrobp.2007.04.049 |
0.437 |
|
| 2007 |
Chan N, Milosevic M, Bristow RG. Tumor hypoxia, DNA repair and prostate cancer regression: New targets and new therapies Future Oncology. 3: 329-341. PMID 17547528 DOI: 10.2217/14796694.3.3.329 |
0.52 |
|
| 2007 |
Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 83: 220-30. PMID 17531338 DOI: 10.1016/J.Radonc.2007.04.016 |
0.513 |
|
| 2007 |
Warde P, Tsuji D, Bristow R. A randomized phase III study of neoadjuvant hormonal therapy in patients with localized prostate cancer. Clinical Genitourinary Cancer. 5: 235-7. PMID 17239279 DOI: 10.3816/Cgc.2006.N.043 |
0.407 |
|
| 2007 |
Supiot S, Zhao H, Weiman K, Hill R, Bristow R. 2BA PRIMA-1met as a potential prostate cancer radiosensitizer under normoxia and hypoxia European Journal of Cancer Supplements. 5: 10. DOI: 10.1016/S1359-6349(07)70102-7 |
0.519 |
|
| 2007 |
Bayley A, Rosewall T, Kelly V, Bristow R, Chung P, Craig T, Kong V, Menard C, Warde P, Catton C. Dose Escalated IMRT to Pelvic Lymph Nodes and Prostate/Seminal Vesicles for High Risk Prostate Cancer–Feasibility and Toxicity International Journal of Radiation Oncology*Biology*Physics. 69: S341-S342. DOI: 10.1016/J.Ijrobp.2007.07.1421 |
0.423 |
|
| 2006 |
Dellaire G, Ching RW, Ahmed K, Jalali F, Tse KC, Bristow RG, Bazett-Jones DP. Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. The Journal of Cell Biology. 175: 55-66. PMID 17030982 DOI: 10.1083/Jcb.200604009 |
0.305 |
|
| 2006 |
Martin J, Bristow R, Warde P. Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy. The Canadian Journal of Urology. 63-7. PMID 16672132 |
0.315 |
|
| 2006 |
Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents part I: Targeting ATM-ATR checkpoints, DNA repair, and the proteasome Seminars in Radiation Oncology. 16: 51-58. PMID 16378907 DOI: 10.1016/J.Semradonc.2005.08.007 |
0.335 |
|
| 2006 |
Supiot S, Hill R, Bristow R. 539 POSTER Nutlin-3 radiosensitizes prostate cancer cell lines independent of p53 status European Journal of Cancer Supplements. 4: 163-164. DOI: 10.1016/S1359-6349(06)70544-4 |
0.496 |
|
| 2005 |
Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Annals of the New York Academy of Sciences. 1059: 184-95. PMID 16382054 DOI: 10.1196/Annals.1339.049 |
0.35 |
|
| 2005 |
Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Research. 65: 11597-604. PMID 16357170 DOI: 10.1158/0008-5472.Can-05-2119 |
0.337 |
|
| 2005 |
Al Rashid ST, Dellaire G, Cuddihy A, Jalali F, Vaid M, Coackley C, Folkard M, Xu Y, Chen BP, Chen DJ, Lilge L, Prise KM, Bazett Jones DP, Bristow RG. Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Research. 65: 10810-21. PMID 16322227 DOI: 10.1158/0008-5472.Can-05-0729 |
0.315 |
|
| 2005 |
Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, Bristow RG. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 76: 168-76. PMID 16026872 DOI: 10.1016/J.Radonc.2005.06.025 |
0.515 |
|
| 2005 |
Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: Clinical and translational issues Cancer. 104: 891-905. PMID 16007687 DOI: 10.1002/Cncr.21257 |
0.469 |
|
| 2005 |
Nichol A, Chung P, Lockwood G, Rosewall T, Divanbiegi L, Sweet J, Toi A, Bayley A, Bristow R, Crook J, Gospodarowicz M, McLean M, Milosevic M, Warde P, Catton C. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 76: 11-7. PMID 15990187 DOI: 10.1016/J.Radonc.2005.06.002 |
0.493 |
|
| 2005 |
Horsburgh S, Matthew A, Bristow R, Trachtenberg J. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. The Prostate. 65: 124-9. PMID 15880530 DOI: 10.1002/Pros.20278 |
0.494 |
|
| 2005 |
Kumaravel TS, Bristow RG. Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells sing Comet-FISH Breast Cancer Research and Treatment. 91: 89-93. PMID 15868435 DOI: 10.1007/S10549-004-5780-0 |
0.313 |
|
| 2004 |
Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG. Defective DNA strand break repair after DNA damage in prostate cancer cells: Implications for genetic instability and prostate cancer progression Cancer Research. 64: 8526-8533. PMID 15574758 DOI: 10.1158/0008-5472.Can-04-1601 |
0.505 |
|
| 2004 |
Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Molecular and Cellular Biology. 24: 8504-18. PMID 15367671 DOI: 10.1128/Mcb.24.19.8504-8518.2004 |
0.41 |
|
| 2004 |
Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: Yes or no? Cancer and Metastasis Reviews. 23: 237-257. PMID 15197326 DOI: 10.1023/B:Canc.0000031764.81141.E4 |
0.346 |
|
| 2004 |
Bayley AJ, Catton CN, Haycocks T, Kelly V, Alasti H, Bristow R, Catton P, Crook J, Gospodarowicz MK, McLean M, Milosevic M, Warde P. A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 70: 37-44. PMID 15036850 DOI: 10.1016/J.Radonc.2003.08.007 |
0.399 |
|
| 2004 |
Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, Catton C, Catton P, Crook J, Gospodarowicz M, McLean M, Warde P, Hill RP. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 58: 750-7. PMID 14967430 DOI: 10.1016/S0360-3016(03)01621-3 |
0.479 |
|
| 2004 |
Al Rashid S, Jalali F, Lilge L, Bristow R. Radiation-induced phosphoforms of p53 as biomarkers of DNA-dsbs in situ International Journal of Radiation Oncology*Biology*Physics. 60: S344. DOI: 10.1016/J.Ijrobp.2004.07.171 |
0.313 |
|
| 2004 |
Milosevic M, Bristow R, Chung P, Panzarella T, Toi A, Hill R. Prostate cancer hypoxia correlates with poor patient outcome following treatment with radiotherapy International Journal of Radiation Oncology*Biology*Physics. 60: S236-S237. DOI: 10.1016/J.Ijrobp.2004.06.198 |
0.492 |
|
| 2003 |
Catton C, Milosevic M, Warde P, Bayley A, Crook J, Bristow R, Gospodarowicz M. Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management. The Urologic Clinics of North America. 30: 751-63. PMID 14680312 DOI: 10.1016/S0094-0143(03)00051-X |
0.411 |
|
| 2003 |
Ma BBY, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents Journal of Clinical Oncology. 21: 2760-2776. PMID 12860956 DOI: 10.1200/Jco.2003.10.044 |
0.32 |
|
| 2003 |
Bristow RG, Peacock J, Jang A, Kim J, Hill RP, Benchimol S. Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53. Oncogene. 22: 2960-6. PMID 12771947 DOI: 10.1038/Sj.Onc.1206405 |
0.329 |
|
| 2003 |
Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: Role of apoptotic and clonogenic cell kill Prostate Cancer and Prostatic Diseases. 6: 73-85. PMID 12664070 DOI: 10.1038/Sj.Pcan.4500628 |
0.479 |
|
| 2003 |
Chung P, Gospodarowicz M, Yi Q, Catton C, Milosevic M, Warde P, McLean M, Bristow R. Outcome of radical radiotherapy for invasive bladder cancer International Journal of Radiation Oncology*Biology*Physics. 57: S177-S178. DOI: 10.1016/S0360-3016(03)00966-0 |
0.374 |
|
| 2002 |
Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, De Stanchina E, Bristow RG, Suda T, Lowe SW, Jeggo PA, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Molecular and Cellular Biology. 22: 6521-32. PMID 12192050 DOI: 10.1128/Mcb.22.18.6521-6532.2002 |
0.303 |
|
| 2002 |
Catton C, Chung P, Haycocks T, Warde P, Alasti H, Bayley A, Bristow R, Crook J, Gospodarowicz M, McLean M, Milosevic M. Hypofractionated intensity modulated radiation therapy for prostate cancer International Journal of Radiation Oncology*Biology*Physics. 54: 188. DOI: 10.1016/S0360-3016(02)03382-5 |
0.486 |
|
| 1998 |
Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, Witterick IP, Payne D, Liu FF, McLean M, Waldron J, Cummings BJ. T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control International Journal of Radiation Oncology Biology Physics. 41: 347-353. PMID 9607350 DOI: 10.1016/S0360-3016(98)00062-5 |
0.346 |
|
| 1998 |
Bristow RG, Hu Q, Jang A, Chung S, Peacock J, Benchimol S, Hill R. Radioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation Oncogene. 16: 1789-1802. PMID 9583677 DOI: 10.1038/Sj.Onc.1201935 |
0.328 |
|
| 1996 |
Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy Radiotherapy and Oncology. 40: 197-223. PMID 8940748 DOI: 10.1016/0167-8140(96)01806-3 |
0.342 |
|
| 1996 |
Bristow RG, Brail L, Jang A, Peacock J, Chung S, Benchimol S, Hill RP. P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection International Journal of Radiation Oncology Biology Physics. 34: 341-355. PMID 8567335 DOI: 10.1016/0360-3016(95)02023-3 |
0.319 |
|
| 1991 |
Pardo FS, Bristow RG, Taghian A, Ong A, Borek C. Role of transfection and clonal selection in mediating radioresistance. Proceedings of the National Academy of Sciences of the United States of America. 88: 10652-6. PMID 1961732 DOI: 10.1073/Pnas.88.23.10652 |
0.304 |
|
| 1990 |
Bristow RG, Hill RP. Comparison between in vitro radiosensitivity and in vivo radioresponse in murine tumor cell lines II: in vivo radioresponse following fractionated treatment and in vitro/in vivo correlations International Journal of Radiation Oncology, Biology, Physics. 18: 331-345. PMID 2303364 DOI: 10.1016/0360-3016(90)90098-5 |
0.326 |
|
| 1990 |
Bristow RG, Hardy PA, Hill RP. Comparison between in vitro radiosensitivity and in vivo radioresponse of murine tumor cell lines I: parameters of in vitro radiosensitivity and endogenous cellular glutathione levels International Journal of Radiation Oncology, Biology, Physics. 18: 133-145. PMID 2298617 DOI: 10.1016/0360-3016(90)90277-Q |
0.317 |
|
| Show low-probability matches. |